WO2023155682A1 - Pregabalin composition suitable for powder tableting and use thereof - Google Patents
Pregabalin composition suitable for powder tableting and use thereof Download PDFInfo
- Publication number
- WO2023155682A1 WO2023155682A1 PCT/CN2023/074166 CN2023074166W WO2023155682A1 WO 2023155682 A1 WO2023155682 A1 WO 2023155682A1 CN 2023074166 W CN2023074166 W CN 2023074166W WO 2023155682 A1 WO2023155682 A1 WO 2023155682A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pregabalin
- product
- particle size
- granulation
- mixing
- Prior art date
Links
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 title claims abstract description 123
- 229960001233 pregabalin Drugs 0.000 title claims abstract description 120
- 239000000203 mixture Substances 0.000 title claims abstract description 29
- 239000000843 powder Substances 0.000 title abstract description 21
- 239000002245 particle Substances 0.000 claims abstract description 80
- 239000013078 crystal Substances 0.000 claims abstract description 70
- 239000000463 material Substances 0.000 claims abstract description 32
- 239000000796 flavoring agent Substances 0.000 claims abstract description 21
- 239000000314 lubricant Substances 0.000 claims abstract description 16
- 239000007884 disintegrant Substances 0.000 claims abstract description 13
- 239000000945 filler Substances 0.000 claims abstract description 13
- 235000013355 food flavoring agent Nutrition 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims description 75
- 238000002156 mixing Methods 0.000 claims description 69
- 229940079593 drug Drugs 0.000 claims description 59
- 238000005469 granulation Methods 0.000 claims description 46
- 230000003179 granulation Effects 0.000 claims description 46
- 239000008187 granular material Substances 0.000 claims description 40
- 238000002360 preparation method Methods 0.000 claims description 40
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 28
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 18
- 229930195725 Mannitol Natural products 0.000 claims description 18
- 239000000594 mannitol Substances 0.000 claims description 18
- 235000010355 mannitol Nutrition 0.000 claims description 18
- 235000019359 magnesium stearate Nutrition 0.000 claims description 14
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 13
- 229960000913 crospovidone Drugs 0.000 claims description 13
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 13
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 13
- 239000004376 Sucralose Substances 0.000 claims description 11
- 235000019634 flavors Nutrition 0.000 claims description 11
- 238000009702 powder compression Methods 0.000 claims description 11
- 235000019408 sucralose Nutrition 0.000 claims description 11
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 11
- 238000007873 sieving Methods 0.000 claims description 9
- 108010011485 Aspartame Proteins 0.000 claims description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 5
- 239000000605 aspartame Substances 0.000 claims description 5
- 235000010357 aspartame Nutrition 0.000 claims description 5
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 5
- 229960003438 aspartame Drugs 0.000 claims description 5
- 239000000741 silica gel Substances 0.000 claims description 5
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 4
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 229920000881 Modified starch Polymers 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 235000010358 acesulfame potassium Nutrition 0.000 claims description 3
- 229960004998 acesulfame potassium Drugs 0.000 claims description 3
- 239000000619 acesulfame-K Substances 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 229940109275 cyclamate Drugs 0.000 claims description 3
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical group OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 235000010356 sorbitol Nutrition 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 2
- 239000004384 Neotame Substances 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical group [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 235000010980 cellulose Nutrition 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 2
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 2
- 229910002055 micronized silica Inorganic materials 0.000 claims description 2
- 235000019426 modified starch Nutrition 0.000 claims description 2
- 235000019412 neotame Nutrition 0.000 claims description 2
- HLIAVLHNDJUHFG-HOTGVXAUSA-N neotame Chemical compound CC(C)(C)CCN[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 HLIAVLHNDJUHFG-HOTGVXAUSA-N 0.000 claims description 2
- 108010070257 neotame Proteins 0.000 claims description 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims 1
- 238000009826 distribution Methods 0.000 abstract description 16
- 239000000126 substance Substances 0.000 abstract description 4
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 239000000047 product Substances 0.000 description 100
- 239000002994 raw material Substances 0.000 description 52
- 239000003826 tablet Substances 0.000 description 52
- 238000000034 method Methods 0.000 description 50
- 230000008569 process Effects 0.000 description 28
- 239000008186 active pharmaceutical agent Substances 0.000 description 19
- 239000006191 orally-disintegrating tablet Substances 0.000 description 19
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 15
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 15
- 239000008108 microcrystalline cellulose Substances 0.000 description 15
- 229940016286 microcrystalline cellulose Drugs 0.000 description 15
- 238000010298 pulverizing process Methods 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 238000005070 sampling Methods 0.000 description 12
- 235000019640 taste Nutrition 0.000 description 12
- 238000009478 high shear granulation Methods 0.000 description 11
- 230000008859 change Effects 0.000 description 9
- 238000007907 direct compression Methods 0.000 description 9
- 239000000686 essence Substances 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 9
- 235000006679 Mentha X verticillata Nutrition 0.000 description 8
- 235000002899 Mentha suaveolens Nutrition 0.000 description 8
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 238000004090 dissolution Methods 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- 238000004513 sizing Methods 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 238000007906 compression Methods 0.000 description 5
- 230000006835 compression Effects 0.000 description 5
- 239000012738 dissolution medium Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000005550 wet granulation Methods 0.000 description 5
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 4
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 3
- 229910000388 diammonium phosphate Inorganic materials 0.000 description 3
- 235000019838 diammonium phosphate Nutrition 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000000889 atomisation Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 239000007891 compressed tablet Substances 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000005243 fluidization Methods 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229940009697 lyrica Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 229940083542 sodium Drugs 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 235000020985 whole grains Nutrition 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- NUFKRGBSZPCGQB-FLBSXDLDSA-N (3s)-3-amino-4-oxo-4-[[(2r)-1-oxo-1-[(2,2,4,4-tetramethylthietan-3-yl)amino]propan-2-yl]amino]butanoic acid;pentahydrate Chemical compound O.O.O.O.O.OC(=O)C[C@H](N)C(=O)N[C@H](C)C(=O)NC1C(C)(C)SC1(C)C.OC(=O)C[C@H](N)C(=O)N[C@H](C)C(=O)NC1C(C)(C)SC1(C)C NUFKRGBSZPCGQB-FLBSXDLDSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 239000004377 Alitame Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 206010061172 Gastrointestinal injury Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 235000011430 Malus pumila Nutrition 0.000 description 1
- 235000015103 Malus silvestris Nutrition 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 239000004695 Polyether sulfone Substances 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 235000019409 alitame Nutrition 0.000 description 1
- 108010009985 alitame Proteins 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000573 anti-seizure effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000007961 artificial flavoring substance Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- -1 glidants Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000003402 intramolecular cyclocondensation reaction Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008368 mint flavor Substances 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 229920006393 polyether sulfone Polymers 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Definitions
- the invention belongs to the field of medicine, and in particular relates to a pregabalin composition suitable for powder compression.
- the immediate-release oral solid preparations of pregabalin on the market are tablets, capsules, and orally disintegrating tablets. Compared with ordinary tablets and capsules, orally disintegrating tablets can quickly disintegrate in the oral cavity under the condition of no water or only a small amount of water, especially suitable for the elderly, children, and patients with difficulty swallowing.
- Pregabalin or (S)-(+)-3-aminomethyl-5-methyl-hexanoic acid can bind to the ⁇ -2- ⁇ ( ⁇ 2 ⁇ ) subunit of calcium channels and is involved in brain neuronal activity
- the regulation of related endogenous inhibitory neurotransmitter ⁇ -aminobutyric acid (GABA) is related.
- GABA ⁇ -aminobutyric acid
- pregabalin has anti-seizure activity and is indicated for the treatment of epilepsy, pain, physiological disorders associated with psychomotor stimuli, inflammation, gastrointestinal injury, alcoholism, insomnia, Fibromyalgia and various psychiatric disorders including anxiety, depression, mania and bipolar disorder.
- Pregabalin is approved in the United States for the treatment of diabetic peripheral neuropathy, postherpetic neuralgia, and as an adjunctive treatment for partial-onset seizures in adults.
- Pregabalin is available as an immediate release (IR) formulation in capsules and administered to patients 2 or 3 times daily (BID or TID).
- IR immediate release
- BID time when patients prefer once-daily dosing to 2 or more daily doses, especially in older patients and patients taking multiple medications, and once-daily dosing is often Patient compliance can be improved. Dosing once a day can also reduce or avoid potential side effects by reducing the maximum concentration of the drug in the blood (CMAX), and can also improve the efficacy of the drug by increasing the minimum concentration in the blood (CMIN).
- CMAX maximum concentration of the drug in the blood
- CMIN minimum concentration in the blood
- Pregabalin drug molecule is a gamma-amino acid (GABA) protein receptor antagonist.
- GABA gamma-amino acid
- filler excipients such as lactose will accelerate intramolecular cyclization of pregabalin to generate lactam impurities.
- Pregabalin raw materials are mostly crystalline crystalline particles with poor compressibility, which cannot meet the requirements of conventional powder direct compression or dry granulation.
- the powder direct compression process is suitable for drugs that are easy to change color and decompose when exposed to moisture or heat. Its most significant advantage is that it reduces the cost of equipment and operation.
- the material particles for powder direct compression should have good fluidity and compressibility , a certain thickness or crystal form, otherwise it is easy to appear plugging and unqualified product properties during the production process. Therefore improving the compressibility of material is the difficulty of preparing pregabalin orally disintegrating tablet preparation.
- Pregabalin is a polymorphic drug, including anhydrous form, hemihydrate form, crystal form I-IV and alpha form.
- the specific crystalline form combination of a polymorphic drug has an important impact on the physical properties of the product, such as storage, stability, compressibility, bulk density (important in formulation and product manufacturing) and dissolution rate (in determining bioavailability have a significant impact).
- crystal habit is the abbreviation of crystal habit, also known as crystal habit, crystal habit, crystal habit, crystal addiction.
- the classification of crystal habits is usually descriptive, not very strict, and it is difficult to find a clear number of categories and classification standards.
- the common classification of crystal habits can be divided into layered, dendritic, blade-shaped, needle-shaped, lenticular, and flake according to the appearance of the crystal; according to the angle between the crystal plane and the crystal plane, it can be divided into: prism, pyramid, and plate; according to the polyhedron Divided into: cube, octahedron, dodecahedron; divided into: fibrous, grape-like, radial, massive according to the aggregation state of the single crystal; multiple crystal habits can also exist under one crystal form of the same substance.
- the physical properties of drug crystal form and crystal habit are very important in drug processing, which may affect the compressibility and fluidity of intermediate products.
- CN00812588 provides a method for preparing taste-masked granules of immediate-release drugs, which uses a binder to granulate the mixed powder of active substance, granule disintegrant, penetrant and sweetener, and then uses a coating agent to granulate Taste masking.
- the dissolution rate of the product after coating is about 10 percentage points slower than that of the reference preparation (Lyrica) in 5 minutes, so it cannot be released quickly, and the bioavailability is low, and the coated tablet can only be swallowed, not Chewing, the actual taking convenience is not high.
- CN103271888 mentions that pregabalin crude drug has poor compressibility, and provides pregabalin medicine (10%-50%), disintegrant crospovidone (5%-30%), microcrystalline cellulose (20% -80%), the rest are prescriptions for flavoring agents, glidants, lubricants; the preparation process is: pregabalin, flavoring agents, microcrystalline cellulose, and disintegrants are mixed in a wet granulator, and an appropriate amount of The water is used for granulation, after granulation, it is dried and sieved, the sieved granules are mixed with the remaining excipients, and the tablets with the required hardness are pressed.
- Pregabalin powder has poor compressibility
- the pregabalin orally disintegrating tablet developed by the invention overcomes the problem of poor compressibility of pregabalin.
- the invention found through many tests that the compressibility of the material can be improved through the granulation process, but the product pressed by the material after granulation has obvious taste problems, the taste is gritty, and the disintegration is slow;
- the finished product prepared by the powder direct pressing process melts in the mouth and has a soft and glutinous taste. Therefore, in order to retain the soft and waxy mouthfeel of pregabalin orally disintegrating tablets, the taste of the product should not be abandoned in order to improve the compressibility of the material by using the granulation process.
- the process steps are relatively complicated, the process of wet granulation requires high energy consumption and takes a long time, and the hot and humid conditions in the processing process will also cause unnecessary stability risks.
- CN111096953 provides a pregabalin orally disintegrating tablet using silicified microcrystalline cellulose powder that can be directly compressed into tablets and its preparation method. It premixes pregabalin and silicified microcrystalline cellulose, then mixes it with other auxiliary materials, and then performs powder direct compression. Its prescription ratio is pregabalin drug (10%-30%), disintegrant crospovidone (5%-20%), filler silicified microcrystalline cellulose, spray-dried mannitol 200SD (10%-80%) %), lubricant (0.5%-2%), flavoring agent (1%-3%). The method can improve the compressibility and fluidity of the material so that the prepared orally disintegrating tablet has excellent stability. But silicified microcrystalline cellulose is a relatively expensive auxiliary material, its price is 3 to 4 times that of general microcrystalline cellulose, and the prescription dosage of microcrystalline cellulose is 20% to 40%, the increase of its cost will Not conducive to product marketing.
- improving the compressibility of pregabalin orally disintegrating tablets can be considered by adding excipients with better compressibility or reducing the proportion of pregabalin in the prescription, but this will increase the tablet weight and size problems, and also reduce the number of tablets produced in a single batch.
- the way of increasing the binder will affect the disintegration behavior of the product and prolong the disintegration time of the product.
- the wet granulation method can effectively improve the compressibility of the granules, but such a process will increase the cost of processing and time in the preparation, and at the same time, exposure to damp and heat factors will increase the risk of product impurities.
- most methods to improve the compressibility of pregabalin orally disintegrating tablets are by adding excipients with better compressibility or performing wet granulation. These methods will increase the cost of the product and affect the disintegration time limit of the product situation etc.
- the technical problem to be solved by this invention is to provide a kind of pregabalin composition suitable for powder compression for the deficiencies of the prior art.
- Compounding with additives, lubricants and disintegrants can significantly improve the compressibility of materials, and through a simple mixing and tableting process, pregabalin orally disintegrating tablets of good quality can be produced.
- the present invention discloses a pregabalin composition suitable for powder compression, the active component pregabalin is pregabalin with a square crystal habit, and the particle size range is D90: 350-600 ⁇ m , the dosage accounts for 20%-50% of the total weight of the prescription.
- the pregabalin composition also includes fillers, disintegrants, flavoring agents, essences and lubricants.
- the dosage of the filler is 0.0% to 80.0%, the flavoring agent is 0.1% to 15.0%, the disintegrant is 1.0% to 20.0%, the lubricant is 0.5% to 3.0%, preferably, the dosage of the filler is 30.0% ⁇ 70.0%, flavoring agent 1.0% ⁇ 5.0%, disintegrant 1.0% ⁇ 10.0%, lubricant 0.5% ⁇ 3.0%, glidant 0.1% ⁇ 1.0%, the above percentages are the percentages of the total weight of the prescription.
- the filler is any one or both of cellulose derivatives and starch derivatives.
- the filler is such as cyclodextrin, dextrin, microcrystalline cellulose, pregelatinized starch, sodium carboxymethyl starch, mannitol, sorbitol, xylitol, glucose, methylcellulose, hydroxypropyl starch etc.; preferably, the filler is at least one of microcrystalline cellulose, calcium hydrogen phosphate dihydrate, mannitol or lactose.
- the disintegrant is at least one of croscarmellose sodium, crospovidone, low-substituted hydroxypropyl cellulose or sodium carboxymethyl starch; the glidant is micropowder silica gel, talc Any one or more of powder, magnesium stearate.
- the lubricant is at least one of sodium stearyl fumarate, magnesium stearate, micronized silica gel and talcum powder.
- Described corrective agent is cyclamate (cyclamate), acesulfame potassium (acesulfame potassium, A-K sugar), aspartame (aspartame, sweetener) , aspartame (alitame), neotame, sucralose, sucrose, sorbitol, mannitol, glucose in any one or more;
- the flavor is a natural flavor or a synthetic flavor, It preferably includes at least one of milk flavor, grape flavor, strawberry flavor, vanillin, apple flavor, orange flavor, banana flavor, orange oil and other natural or artificial flavors.
- the composition also includes a glidant, and the amount of the glidant accounts for 0.1-1.0% of the total mass of the prescription.
- the glidant is any one or more of micropowder silica gel, talcum powder, and magnesium stearate. .
- the present invention further proposes the application of the above pregabalin composition in the preparation of pregabalin tablets.
- the present invention proposes a preparation method of pregabalin tablet, comprising the steps of:
- pregabalin is pregabalin with a square crystal habit, and the particle size range is D90: 350 ⁇ 600 ⁇ m;
- the sieve aperture of the granulator is 0.8mm, and the granulation speed is 300-700rpm.
- the tablet prepared by the invention can be used as an immediate-release preparation for treating epilepsy and neuropathic pain.
- the present invention has the following advantages:
- the present invention has obtained through a large number of experiments and researches by the inventors: the pregabalin bulk drug with a particle size range D90 of 350 to 600 ⁇ m and a square crystal habit is compounded with fillers, lubricants and disintegrants, The compressibility of materials can be significantly improved, and pregabalin orally disintegrating tablets of good quality can be prepared through a simple mixing and tableting process.
- the rapid-release preparation can realize the rapid release of the active ingredient pregabalin, so that the effective blood drug concentration can be reached more quickly after oral administration; compared with the traditional capsule preparation, the prepared rapid-release preparation of the present invention has fast onset of action, fast absorption, and stable The effect, the taste is cool and slightly Sweet, melt-in-the-mouth, soft and glutinous taste, no unbearable bitterness, can improve patient compliance.
- the preparation method of the present invention uses a door-type granulator to process the pregabalin bulk drug to obtain the pregabalin bulk drug with a specific crystal habit and a certain particle size range, and then by mixing with various conventional auxiliary materials, A material granule with excellent compressibility is prepared by a relatively simple process for preparing orally disintegrating pregabalin tablets.
- the process has the advantages of simple operation, mature control standard, low cost and high degree of industrialization;
- the present invention finds that the melting point of lipid excipients is relatively low by conducting stability research experiments on reference preparations, which will affect the changes in product quality indicators during the stability investigation process, such as appearance, related substances, dissolution, hardness, etc. , and the use of these higher-priced accessories will also increase product costs.
- the present invention simplifies the types of auxiliary materials and controls the particle size and crystal habit of the pregabalin crude drug, so as to reduce the product cost and prepare the stable pregabalin quick-release preparation.
- Fig. 1 is the microscopic picture of the bulk drug used in product 1;
- Fig. 2 is the microscopic picture of the bulk drug used in product 2;
- Fig. 3 is a picture of the particle size distribution of the bulk drug used in product 1;
- Fig. 4 is the particle size distribution picture of the raw material drug used in product 2;
- Fig. 5 is a microscope picture of the raw material drug used in product 3;
- Fig. 6 is a microscope picture of the bulk drug used in product 4.
- Fig. 7 is a microscope picture of the raw material drug used in product 5;
- Fig. 8 is a microscope picture of the bulk drug used in product 6;
- Fig. 9 is a microscope picture of the bulk drug used in product 7;
- Figure 10 is a picture of the dissolution curves of Product 1, Product 2 and the reference preparation.
- the product detection method is as follows:
- Method for measuring the particle size of the raw material Weigh about 0.3g of the dispersant Span-85 into a 250ml beaker, then add an accurately measured 120ml of n-heptane to obtain a certain proportion of Span-85 n-heptane solution, and place it in a trace In the disperser, stir until the background is stable, measure the background signal, then add 0.1g pregabalin sample, stir for 60s to obtain a certain concentration of the sample to be tested, place the sample in the micro-wet sampling window of the laser particle size analyzer, and Run the corresponding measurement method file according to the relevant parameter items, and take the arithmetic mean value of the three measurement results to obtain the particle size data of the raw material drug.
- the meaning of particle size distribution is to use specific instruments and methods to measure the percentage of particles of different particle sizes in the powder sample to the total particle volume (or number, etc.).
- D10 The accumulation of a sample (add the percentage of all particle sizes in front or behind), the corresponding particle size when the particle size distribution number reaches 10%. Its physical meaning is that the particles whose particle size is smaller (or larger) account for 10%.
- D90 The particle size corresponding to when the cumulative particle size distribution number of a sample reaches 90%. Its physical meaning is that the particles whose particle size is smaller (or larger) account for 90%.
- D50 The particle size corresponding to when the cumulative particle size distribution percentage of a sample reaches 50%.
- D50 is also called the median diameter or median particle diameter. It does not indicate the average particle size of the powder, but indicates that the average particle size of the powder has other parameters, such as D(4,3), D(3,2) and so on. Both D(4,3) and D(3,2) represent the average particle diameter on the basis of volume.
- the full name of D(4,3) is "mass moment volume average particle diameter" and is referred to as volume average diameter for short.
- the full name of D(3,2) is "volume area average particle diameter", and it is referred to as area average diameter for short.
- Di represents the average particle size of the i-th particle size interval
- fi represents the i-th one.
- D(3,2) and D(4,3) can be understood as follows: for laser particle size analyzers, the closer to spherical particles, the more accurate the measurement results. Then, when the values of D(3,2) and D(4,3) are closer, it means that the shape of the sample particles is more regular and the particle size distribution is more concentrated. The larger the difference, the more irregular the shape of the sample particles and the wider the particle size distribution.
- the crystal habit appearance of raw materials is observed and measured through a microscope. Take 0.01g of pregabalin bulk drug on the glass slide On, drop 1 drop of liquid paraffin to disperse.
- the microscope eyepiece parameter is 10 times, and the objective lens parameter is 5 times. Observe and take pictures with uniform dispersion of particles and sufficient light.
- Pregabalin (D90 is 900 ⁇ m, crystal habit is long needle-shaped and square) is sized by a door-type granulator with a 0.8 mm sieve, and the granulation speed is 700 rpm. After sizing, the D90 of pregabalin is 500 ⁇ m , The crystal habit is square;
- pregabalin (D90 is 900 ⁇ m, crystal habit is long needle-shaped and square), microcrystalline cellulose, mannitol, sucralose, sodium saccharin, crospovidone SH-SL10 and mint essence are mixed in a square cone mixing barrel, the mixing speed is 10rpm, and the mixing time is 20min;
- the D90 of the API of product 1 after being granulated by the portal granulator is 500 ⁇ m, and the difference between D(4,3) and D(3,2) is 74 ⁇ m.
- the D90 of product 2 API is 900 ⁇ m, and the difference between D(4,3) and D(3,2) is 575 ⁇ m.
- the difference between product 1 API D(3,2) and D(4,3) is smaller, indicating that the shape of product 1 API particles is more regular, and the particle size distribution is concentrated. According to its microscopic photos, it shows that its The crystal habit is square crystal.
- Tablet results show that the crystal habit is mainly square crystal, and the product 1 whose D90 is 500 ⁇ m is more than the product 2 whose crystal habit is mainly long needle-like crystal and square crystal mixed crystal in the raw material medicine, and its material fluidity is better, and the pressed tablet is brittle The degree is lower and the maximum compressive hardness is higher. Therefore, the use of pregabalin raw materials whose crystal habit is mainly fang crystal can effectively improve the fluidity and compressibility of the material, and prepare pregabalin orally disintegrating tablets with excellent properties.
- Fig. 10 is the dissolution curve chart of product 1 and product 2 and reference preparation.
- the 0.06M HCL-paddle method is used for detection, and the specific detection steps are:
- Dissolution medium 0.06M hydrochloric acid solution
- preparation steps Measure 5.4ml of hydrochloric acid, dilute with water to 1000ml, shake well, and get ready.
- Control solution take about 16 mg of pregabalin reference substance, accurately weigh it, place it in a 100 mL volumetric flask, add dissolution medium to dissolve and quantitatively dilute to the mark, shake well (concentration is about 160 ⁇ g/ml). Prepare two copies in parallel.
- Dissolution medium 0.06M hydrochloric acid
- Dissolution medium temperature 37 ⁇ 0.5°C
- Dissolution medium volume 900ml.
- Sample solution treatment use a 0.45 ⁇ m water filter head (Jinteng, polyethersulfone, 25mm) to filter, discard 2ml of the initial filtrate, and take the subsequent filtrate as the sample solution.
- the preparation is pregabalin orally disintegrating tablets.
- the pregabalin was first listed in Japan on February 17, 2017.
- the English product name is LYRICA (Lerica), and the Japanese product name is ⁇ OD Tablet.
- the licensee is Pfizer Japan Inc. ( ⁇ Co., Ltd.), the reference preparation is marked as EA6596 in this application.
- the stripping curve of the product of the present invention is similar to that of the reference preparation, and the in vitro results illustrate to a certain extent that the product of the present invention has the same rapid onset and absorption as the reference preparation.
- Pregabalin (D90 is 900 ⁇ m, crystal habit is long needle-shaped and square) is sized by a door-type granulator with a 0.8mm sieve, and the granulation speed is reduced from 700rpm to 300rpm, which is the lowest speed of the equipment.
- the D90 of pregabalin is 550 ⁇ m, and the crystal habit is square;
- the door-type granulator speed is reduced from 700rpm to 300rpm, compared with the bulk drug obtained at the 700rpm granulation speed, the D90 of the raw material drug obtained at the 300rpm granulation speed, the difference between D (4, 3) and D (3, 2) has no difference. obvious change.
- Tablet results show that, compared with product 1 obtained by granulating at 700rpm, there is no significant difference in material fluidity, friability and maximum compressible hardness of product 3 obtained at 300rpm. . Therefore, 700rpm, which has higher production efficiency, should be used as the granulation speed parameter of the gantry granulator in the subsequent production process, which is simple and easy to control.
- Pregabalin (D90 is 900 ⁇ m, crystal habit is long needle-shaped and square) is sized by a door-type granulator, the 0.8mm sieve is changed to a 0.9mm sieve, and the sizing speed is 700rpm. After sizing, The D90 of pregabalin is 700 ⁇ m, and the crystal habit is long needle-shaped and square.
- Tablet results show that compared with the product 1 of the raw material drug obtained by 0.8 mm sieve granulation, the material fluidity of product 4 of the raw material drug obtained by 0.9 mm sieve granulation slows down, and the friability of the pressed tablet becomes higher. The maximum compressible hardness decreased, and the disintegration time became slower. Therefore, the 0.8mm screen should be used as the screen parameter of the portal granulator in the subsequent production process. The operation is simple and easy to control, and the product quality can be guaranteed.
- Pregabalin (D90 is 900 ⁇ m, crystal habit is long needle-shaped and square) is sized by a door-type granulator, the 0.8mm granulation screen is changed to a 0.7mm sieve, and the granulation speed is 700rpm.
- Pregabalin D90 is 350 ⁇ m, and the crystal habit is square;
- Tablet results show that compared with Product 1 of the bulk drug obtained through 0.8 mm sieve granulation, the material fluidity of Product 5 of the bulk drug obtained through 0.7 mm sieve granulation has no significant change, and the friability of the pressed tablet is slightly reduced. increased, the maximum compressible hardness decreased slightly, and the disintegration time limit was significantly slower. It is speculated that there are more fine powders of raw materials, which tend to adhere to the disintegration instrument screen during disintegration and cannot pass through smoothly, resulting in a longer disintegration time limit. Therefore, the 0.8mm screen should be used as the screen parameter of the portal granulator in the subsequent production process. The operation is simple and easy to control, and the product quality can be guaranteed.
- the granulation process of the portal granulator was changed to pulverization by the traditional Chinese medicine pulverizer.
- the D (4, 3) and D (3, 2) of the raw material medicine obtained by pulverizing the traditional Chinese medicine pulverizer for 4 seconds The difference is smaller, and the D90 is significantly smaller, and the overall particle size is significantly smaller.
- the pregabalin raw material drug obtained by pulverizing the traditional Chinese medicine pulverizer is a square crystal, which is relatively round, but the overall particle size is relatively small, and the D90 is 200 ⁇ m.
- Tablet results show that, compared with product 1 of the raw material drug obtained by 0.8mm sieve granulation, the material fluidity of product 6 of the raw material drug obtained by pulverizing the traditional Chinese medicine pulverizer for 4 seconds is slightly reduced, and the friability of the pressed tablet is significantly increased, the highest The compressible hardness decreased significantly, and the disintegration time limit changed significantly. Slower, it is speculated that there are more fine powders of raw materials, which tend to adhere to the screen of the disintegration instrument during disintegration, and cannot pass through smoothly, resulting in a longer disintegration time limit. Therefore, it is difficult for traditional Chinese medicine pulverization process to replace the door-type granulation process. The pulverization effect of traditional Chinese medicine pulverization process is difficult to control, and the control standard is difficult to determine. Oral disintegration of pregabalin.
- the granulation process of the portal granulator is changed to the pulverization of the universal pulverizer.
- the D (4, 3) and D ( 3, 2) The difference is smaller, and the D90 is significantly smaller, and the overall particle size is significantly smaller.
- the pregabalin raw material drug obtained by pulverizing with a universal pulverizer is a square crystal, which is relatively round, but the overall particle size is relatively small, and the D90 is 250 ⁇ m.
- Tablet results show that compared with the product 1 of the raw material drug obtained by 0.8mm sieve granulation, the material fluidity of the product 7 of the raw material drug obtained by pulverizing the universal pulverizer slightly decreases, and the friability of the pressed tablet increases slightly, the highest The compressible hardness decreased slightly, and the disintegration time was significantly slower. Therefore, it is also difficult for the universal pulverization process to replace the door-type granulation process. The pulverization effect of the universal process is also difficult to control, and the control standards are difficult to determine. It is impossible to obtain pregabalin raw materials with specific crystal habits and a certain particle size range, and the preparation quality is not qualified. orally disintegrating pregabalin tablets.
- the shear speed is 1500rpm
- the stirring speed is 500rpm
- the granulation time is 3min;
- the prepared granules are subjected to 8*8mm wet granulation, and then dried in a fluidized bed at a drying temperature of 45°C and a fluidization wind speed of 60m 3 /h, and the obtained dried granules are then subjected to 0.8mm sieve gate type granulation , the rotation speed of the whole grain is 700rpm;
- the overall powder direct compression process was changed to high-shear granulation tablet compression.
- Tablet results showed that compared with the pregabalin orally disintegrating tablet product 1 obtained by powder direct compression, the pregabalin obtained by high-shear granulation Orally disintegrating tablet product 8 has little change in material fluidity, little change in the friability of the compressed tablet, a slight decrease in the maximum compressible hardness, and a significantly slower disintegration time limit, which is presumed to be the raw material medicine after high-shear granulation
- the particles are wrapped and covered, and it is not easy to dissolve and disperse during disintegration, which causes the material particles to adhere to the screen of the disintegration instrument and cannot pass through smoothly, resulting in a longer disintegration time limit.
- the high-shear granulation tableting process is not suitable for the preparation of pregabalin mouth-disintegrating tablets.
- the high-shear granulation tableting process is also relatively cumbersome, the production efficiency is low, the control standard is difficult to determine, and it is difficult to obtain qualified quality tablets. Oral disintegration of pregabalin.
- Pregabalin (D90 is 900 ⁇ m, crystal habit is long needle-shaped and square) is sized by a portal granulator with a 0.8mm sieve at a sizing speed of 700rpm.
- 3Mix microcrystalline cellulose pregabalin after granulation, sucralose, sodium saccharin, crospovidone SH-SL10, and mint essence in a high-shear granulator, with a shearing speed of 500 rpm and a stirring speed of 500 rpm. 200rpm, mixing time 10min;
- the prepared granules are subjected to 8*8mm wet granulation, and then dried in a fluidized bed at a drying temperature of 45°C and a fluidization wind speed of 60m 3 /h, and the obtained dried granules are then subjected to 0.8mm sieve gate type granulation , the rotation speed of the whole grain is 700rpm;
- the powder direct compression process was changed as a whole to gate-type granulation of the raw material drug first, and then high-shear granulation and tablet compression.
- the tablet results showed that compared with the pregabalin orally disintegrating tablet product 1 obtained by powder direct compression, The material fluidity of the pregabalin mouth-disintegrating tablet product 9 obtained by gate-type granulation of the raw material drug and then high-shear granulation and tablet compression did not change much, the friability of the compressed tablet did not change much, and the highest compressible hardness There is little change, but the disintegration time limit is still relatively slow. It is speculated that after high-shear granulation, the raw material drug particles are covered after gate-type granulation.
- the disintegration instrument screen cannot pass through smoothly, resulting in a longer disintegration time limit. Therefore, the powder direct compression process is more suitable for the preparation of pregabalin orally disintegrating tablets, and the high-shear granulation tableting process is also relatively cumbersome, the production efficiency is low, the control standard is difficult to determine, and it is difficult to obtain qualified pregabalin Mouth disintegration.
- the particle size range of common pregabalin raw materials sold in the market is about 800-1100 microns, and the crystal habit is elongated needle-shaped and square crystal mixed crystal.
- This pregabalin crude drug has poor compressibility and fluidity, and cannot be used for the preparation of pregabalin orally disintegrating tablets.
- the granulation is sized by a door-type granulator, the size of the sieve is 0.8mm, and the granulation speed is 700rpm, which can efficiently and easily control the preparation of particle sizes ranging from 350 to 600 ⁇ m, D(4,3) and D(3, 2)
- the range of the difference is small, 50-150 ⁇ m, pregabalin API with square crystal habit, this API can effectively improve the fluidity and compressibility of common pregabalin APIs currently on the market,
- the purpose of producing pregabalin orally disintegrating tablets with simple operation, mature control standards, low cost, high industrialization degree and excellent quality is achieved.
- the present invention provides another way of thinking, by preparing pregabalin raw materials with a certain particle size range and specific crystal habit, compared with ordinary pregabalin raw materials, the compressibility of the prepared blended materials Significantly improved, and no additional costly excipients are used in the preparation of the blend.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
Abstract
Provided is a pregabalin composition suitable for powder tableting. The active ingredient pregabalin has a cubic crystal habit, a particle size distribution D90 of 350-600 μm, and a strength of 20%-50% of the weight of the composition. The pregabalin composition further comprises a filler, a disintegrant, a flavoring agent, an essence, and a lubricant. By means of preparing a pregabalin substance with a certain particle size range and a specific crystal habit, compared with conventional pregabalin substances, a blended material with improved compressibility is prepared.
Description
本发明属于医药领域,具体涉及一种适用于粉末压片的普瑞巴林组合物。The invention belongs to the field of medicine, and in particular relates to a pregabalin composition suitable for powder compression.
国际上,上市的普瑞巴林速释口服固体制剂为片剂、胶囊剂、口腔崩解片。与普通的片剂和胶囊剂相比,口腔崩解片可在无水或仅有少量水存在的条件下在口腔中快速崩散,尤其适用于老人、小儿、吞咽困难的病人。Internationally, the immediate-release oral solid preparations of pregabalin on the market are tablets, capsules, and orally disintegrating tablets. Compared with ordinary tablets and capsules, orally disintegrating tablets can quickly disintegrate in the oral cavity under the condition of no water or only a small amount of water, especially suitable for the elderly, children, and patients with difficulty swallowing.
普瑞巴林或(S)-(+)-3-胺基甲基-5-甲基-己酸可以与钙通道的α-2-δ(α2δ)亚单位结合,并且涉及与脑神经元活性的调节相关的内源抑制性神经传递质γ-胺基丁酸(GABA)有关。如美国专利5,563,175所述,普瑞巴林具有抗癫痫发作活性,且适用于治疗以下病症:癫痫、疼痛、与精神运动性刺激物有关的生理病症、炎症、胃肠损伤、酒精中毒、失眠症、纤维肌痛和包括焦虑症、抑郁症、躁狂症和双极型障碍的各种精神失调症。美国已批准普瑞巴林用于治疗糖尿病性末梢神经病变、疱疹后的神经痛以及作为成人局部癫痫发作的辅助治疗。普瑞巴林可以作为胶囊中的立即释放性(IR)配制品使用,并且每日2或3次(BID或TID)施予患者。相较于每日2次或更多次给药,大部分患者更倾向于每日服药一次,尤其对于年长患者和服用多种药物的患者而言,并且每日1次的给药方式通常可以改善患者的顺从性。每日给药一次还可以通过减少在血液中的药物最高浓度(CMAX)从而减轻或避免潜在的副作用,还可通过增加血液中的最低浓度(CMIN)而提高药物功效。Pregabalin or (S)-(+)-3-aminomethyl-5-methyl-hexanoic acid can bind to the α-2-δ (α2δ) subunit of calcium channels and is involved in brain neuronal activity The regulation of related endogenous inhibitory neurotransmitter γ-aminobutyric acid (GABA) is related. As described in U.S. Patent 5,563,175, pregabalin has anti-seizure activity and is indicated for the treatment of epilepsy, pain, physiological disorders associated with psychomotor stimuli, inflammation, gastrointestinal injury, alcoholism, insomnia, Fibromyalgia and various psychiatric disorders including anxiety, depression, mania and bipolar disorder. Pregabalin is approved in the United States for the treatment of diabetic peripheral neuropathy, postherpetic neuralgia, and as an adjunctive treatment for partial-onset seizures in adults. Pregabalin is available as an immediate release (IR) formulation in capsules and administered to patients 2 or 3 times daily (BID or TID). Most patients prefer once-daily dosing to 2 or more daily doses, especially in older patients and patients taking multiple medications, and once-daily dosing is often Patient compliance can be improved. Dosing once a day can also reduce or avoid potential side effects by reducing the maximum concentration of the drug in the blood (CMAX), and can also improve the efficacy of the drug by increasing the minimum concentration in the blood (CMIN).
含有普瑞巴林的口服药物组合物给制剂带来很大的挑战。普瑞巴林药物分子是一种γ-氨基酸(GABA)蛋白受体的拮抗剂。与各种辅料混合后,其中填充剂类辅料例如乳糖,会加速普瑞巴林发生分子内环化生成内酰胺杂质。普瑞巴林原料药多为结晶状晶体颗粒,可压性较差,达不到常规的粉末直压或干法制粒要求。粉末直接压片工艺适用于遇湿、热易变色、分解等药物,其最显著的优势是降低了设备和运行的成本,进行粉末直接压片的物料颗粒应具有良好的流动性、可压性、一定的粗细度或结晶形态,否则生产过程中容易出现塞冲、产品性质不合格等现象。因此提高物料的可压性是制备普瑞巴林口崩片制剂的难点。
Oral pharmaceutical compositions containing pregabalin pose significant formulation challenges. Pregabalin drug molecule is a gamma-amino acid (GABA) protein receptor antagonist. After mixing with various excipients, filler excipients such as lactose will accelerate intramolecular cyclization of pregabalin to generate lactam impurities. Pregabalin raw materials are mostly crystalline crystalline particles with poor compressibility, which cannot meet the requirements of conventional powder direct compression or dry granulation. The powder direct compression process is suitable for drugs that are easy to change color and decompose when exposed to moisture or heat. Its most significant advantage is that it reduces the cost of equipment and operation. The material particles for powder direct compression should have good fluidity and compressibility , a certain thickness or crystal form, otherwise it is easy to appear plugging and unqualified product properties during the production process. Therefore improving the compressibility of material is the difficulty of preparing pregabalin orally disintegrating tablet preparation.
普瑞巴林为多晶型药物,包括无水型、半水型、晶型I~IV以及alpha型。多晶型药物的具体晶型组合对产品的物理性质具有重要影响,例如储存,稳定性,可压缩性,堆密度(在制剂和产品生产中具有重要影响)和溶出度(在确定生物利用度中具有重要影响)。另一方面,一种晶体在一定外界条件下自发生长趋向形成某一种形态的特性,称为晶体习性。晶习是晶体习性的简称,也称晶体习性、结晶习性、晶体惯态、晶癖。晶习的分类通常是描述性的,并不是十分严格,也很难找到明确的类别数量和分类标准。常见的晶习分类可以根据晶体外观分为层状、树突状、刀刃状、针状、透镜状、片状;根据晶面与晶面夹角分为:棱柱、棱锥、板状;根据多面体分为:立方体、八面体、十二面体;根据单晶的聚集状态分为:纤维状、葡萄状、放射状、块状;同一物质的一个晶型下也可以存在多种晶习。药物晶型以及晶习的物理性质在药物加工中是非常重要的,可能会影响到中间产品的可压性和流动性等。Pregabalin is a polymorphic drug, including anhydrous form, hemihydrate form, crystal form I-IV and alpha form. The specific crystalline form combination of a polymorphic drug has an important impact on the physical properties of the product, such as storage, stability, compressibility, bulk density (important in formulation and product manufacturing) and dissolution rate (in determining bioavailability have a significant impact). On the other hand, the characteristic that a crystal grows spontaneously and tends to form a certain shape under certain external conditions is called crystal habit. Crystal habit is the abbreviation of crystal habit, also known as crystal habit, crystal habit, crystal habit, crystal addiction. The classification of crystal habits is usually descriptive, not very strict, and it is difficult to find a clear number of categories and classification standards. The common classification of crystal habits can be divided into layered, dendritic, blade-shaped, needle-shaped, lenticular, and flake according to the appearance of the crystal; according to the angle between the crystal plane and the crystal plane, it can be divided into: prism, pyramid, and plate; according to the polyhedron Divided into: cube, octahedron, dodecahedron; divided into: fibrous, grape-like, radial, massive according to the aggregation state of the single crystal; multiple crystal habits can also exist under one crystal form of the same substance. The physical properties of drug crystal form and crystal habit are very important in drug processing, which may affect the compressibility and fluidity of intermediate products.
CN00812588提供了一种用于制备速释药物掩味颗粒的方法,其使用粘合剂对活性物质、颗粒崩解剂、渗透剂和甜味剂的混合粉末进行制粒,然后使用包衣剂进行包衣掩味。但该方法工艺步骤较多,且包衣后产品比参比制剂(Lyrica)5min溶出度慢约10个百分点,无法做到快速释放,生物利用度低,并且包衣片只能吞服,不能咀嚼,实际服用便利程度不高。CN00812588 provides a method for preparing taste-masked granules of immediate-release drugs, which uses a binder to granulate the mixed powder of active substance, granule disintegrant, penetrant and sweetener, and then uses a coating agent to granulate Taste masking. However, there are many process steps in this method, and the dissolution rate of the product after coating is about 10 percentage points slower than that of the reference preparation (Lyrica) in 5 minutes, so it cannot be released quickly, and the bioavailability is low, and the coated tablet can only be swallowed, not Chewing, the actual taking convenience is not high.
CN103271888提到普瑞巴林原料药可压性差,提供了以普瑞巴林药物(10%-50%),崩解剂交联聚维酮(5%-30%),微晶纤维素(20%-80%),其余为矫味剂、助流剂、润滑剂的处方;制备工艺为:普瑞巴林、矫味剂、微晶纤维素、崩解剂在湿法制粒机中混合,加入适量的水进行制粒,制粒后干燥过筛,过筛后的颗粒和剩余辅料混合,并压制所需硬度的药片。普瑞巴林粉末的可压性较差,该发明开发的普瑞巴林口崩片克服了普瑞巴林可压性较差的问题。该发明通过多次试验发现可以通过制粒工艺来提高物料的可压性,但制粒后物料所压制的产品存在明显的口感问题,其口感为砂砾感,崩散较慢;而本发明通过粉末直压工艺制备的成品入口即化,口感软糯。因此,为保留普瑞巴林口崩片的软糯口感,不应为了使用制粒工艺来提高物料的可压性而放弃产品口感。同时,其工艺步骤较复杂,湿法制粒的工艺能耗高、耗时长,加工过程的湿热条件还会引起不必要的稳定性风险。CN103271888 mentions that pregabalin crude drug has poor compressibility, and provides pregabalin medicine (10%-50%), disintegrant crospovidone (5%-30%), microcrystalline cellulose (20% -80%), the rest are prescriptions for flavoring agents, glidants, lubricants; the preparation process is: pregabalin, flavoring agents, microcrystalline cellulose, and disintegrants are mixed in a wet granulator, and an appropriate amount of The water is used for granulation, after granulation, it is dried and sieved, the sieved granules are mixed with the remaining excipients, and the tablets with the required hardness are pressed. Pregabalin powder has poor compressibility, and the pregabalin orally disintegrating tablet developed by the invention overcomes the problem of poor compressibility of pregabalin. The invention found through many tests that the compressibility of the material can be improved through the granulation process, but the product pressed by the material after granulation has obvious taste problems, the taste is gritty, and the disintegration is slow; The finished product prepared by the powder direct pressing process melts in the mouth and has a soft and glutinous taste. Therefore, in order to retain the soft and waxy mouthfeel of pregabalin orally disintegrating tablets, the taste of the product should not be abandoned in order to improve the compressibility of the material by using the granulation process. At the same time, the process steps are relatively complicated, the process of wet granulation requires high energy consumption and takes a long time, and the hot and humid conditions in the processing process will also cause unnecessary stability risks.
CN111096953提供了一种采用硅化微晶纤维素可粉末直接压片的普瑞巴林口崩片
及其制备方法。其将普瑞巴林与硅化微晶纤维素预混,再与其他辅料混合,再进行粉末直压。其处方比例为普瑞巴林药物(10%-30%),崩解剂交联聚维酮(5%-20%),填充剂硅化微晶纤维素、喷雾干燥甘露醇200SD(10%-80%),润滑剂(0.5%-2%),矫味剂(1%-3%)。其方法可以改善物料可压性和流动性使制备的口崩片稳定性优良。但是硅化微晶纤维素是一种价格较为昂贵的辅料,其价格为一般微晶纤维素的3到4倍,并且微晶纤维素的处方用量比例为20%~40%,其成本的增加将不利于产品的市场销售。CN111096953 provides a pregabalin orally disintegrating tablet using silicified microcrystalline cellulose powder that can be directly compressed into tablets and its preparation method. It premixes pregabalin and silicified microcrystalline cellulose, then mixes it with other auxiliary materials, and then performs powder direct compression. Its prescription ratio is pregabalin drug (10%-30%), disintegrant crospovidone (5%-20%), filler silicified microcrystalline cellulose, spray-dried mannitol 200SD (10%-80%) %), lubricant (0.5%-2%), flavoring agent (1%-3%). The method can improve the compressibility and fluidity of the material so that the prepared orally disintegrating tablet has excellent stability. But silicified microcrystalline cellulose is a relatively expensive auxiliary material, its price is 3 to 4 times that of general microcrystalline cellulose, and the prescription dosage of microcrystalline cellulose is 20% to 40%, the increase of its cost will Not conducive to product marketing.
通常,提高普瑞巴林口崩片制备过程中颗粒的可压性可以考虑通过加入更好可压性的辅料或降低普瑞巴林在处方中的比例,但这样会带来片重增加,尺寸增加的问题,同时也会降低单批次生产片剂的数量。增加粘合剂的方式会影响到产品崩解行为,延长产品崩解时间。采用湿法制粒的方式可以有效提高颗粒的可压性,但这样的工艺会增加制备中加工、时间等成本,同时接触湿热因素会提高产品杂质增加的风险。目前,大多数方法中提高普瑞巴林口崩片制备过程中颗粒的可压性为通过加入更好可压性的辅料或者进行湿法制粒,这些方法会增加产品的成本和影响产品崩解时限情况等。Generally, improving the compressibility of pregabalin orally disintegrating tablets can be considered by adding excipients with better compressibility or reducing the proportion of pregabalin in the prescription, but this will increase the tablet weight and size problems, and also reduce the number of tablets produced in a single batch. The way of increasing the binder will affect the disintegration behavior of the product and prolong the disintegration time of the product. The wet granulation method can effectively improve the compressibility of the granules, but such a process will increase the cost of processing and time in the preparation, and at the same time, exposure to damp and heat factors will increase the risk of product impurities. At present, most methods to improve the compressibility of pregabalin orally disintegrating tablets are by adding excipients with better compressibility or performing wet granulation. These methods will increase the cost of the product and affect the disintegration time limit of the product situation etc.
发明内容Contents of the invention
发明目的:本发明所要解决的技术问题是针对现有技术的不足,提供一种适用于粉末压片的普瑞巴林组合物,通过选用特定晶习和粒径范围的原料药,并进一步和填充剂、润滑剂及崩解剂复配,可以显著提高物料可压性,并经过简单的混合压片工艺,即可制得质量优良的普瑞巴林口崩片。Purpose of the invention: the technical problem to be solved by this invention is to provide a kind of pregabalin composition suitable for powder compression for the deficiencies of the prior art. Compounding with additives, lubricants and disintegrants can significantly improve the compressibility of materials, and through a simple mixing and tableting process, pregabalin orally disintegrating tablets of good quality can be produced.
为了解决上述技术问题,本发明公开了一种适用于粉末压片的普瑞巴林组合物,其活性组分普瑞巴林为具有方形晶习的普瑞巴林,粒径范围为D90:350~600μm,用量占处方总重量的20%-50%。In order to solve the above technical problems, the present invention discloses a pregabalin composition suitable for powder compression, the active component pregabalin is pregabalin with a square crystal habit, and the particle size range is D90: 350-600 μm , the dosage accounts for 20%-50% of the total weight of the prescription.
所述普瑞巴林组合物还包括填充剂、崩解剂、矫味剂、香精和润滑剂。The pregabalin composition also includes fillers, disintegrants, flavoring agents, essences and lubricants.
具体地,所述填充剂用量为0.0%~80.0%,矫味剂0.1%~15.0%,崩解剂1.0%~20.0%,润滑剂0.5%~3.0%,优选地,填充剂用量为30.0%~70.0%,矫味剂1.0%~5.0%,崩解剂1.0%~10.0%,润滑剂0.5%~3.0%,助流剂0.1%~1.0%,上述百分比均为占处方总质量的百分比。Specifically, the dosage of the filler is 0.0% to 80.0%, the flavoring agent is 0.1% to 15.0%, the disintegrant is 1.0% to 20.0%, the lubricant is 0.5% to 3.0%, preferably, the dosage of the filler is 30.0% ~70.0%, flavoring agent 1.0%~5.0%, disintegrant 1.0%~10.0%, lubricant 0.5%~3.0%, glidant 0.1%~1.0%, the above percentages are the percentages of the total weight of the prescription.
其中,所述填充剂为纤维素衍生物和淀粉衍生物中的任意一种或两种。进一步地,
所述填充剂为如环糊精、糊精、微晶纤维素、预胶化淀粉、羧甲基淀粉钠、甘露醇、山梨醇、木糖醇、葡萄糖、甲基纤维素、羟丙基淀粉等;优选地,所述填充剂为微晶纤维素、二水磷酸氢钙、甘露醇或乳糖中的至少一种。Wherein, the filler is any one or both of cellulose derivatives and starch derivatives. further, The filler is such as cyclodextrin, dextrin, microcrystalline cellulose, pregelatinized starch, sodium carboxymethyl starch, mannitol, sorbitol, xylitol, glucose, methylcellulose, hydroxypropyl starch etc.; preferably, the filler is at least one of microcrystalline cellulose, calcium hydrogen phosphate dihydrate, mannitol or lactose.
所述崩解剂为交联羧甲基纤维素钠、交联聚维酮、低取代羟丙基纤维素或羧甲基淀粉钠中的至少一种;所述助流剂为微粉硅胶、滑石粉、硬脂酸镁中的任意一种或几种。The disintegrant is at least one of croscarmellose sodium, crospovidone, low-substituted hydroxypropyl cellulose or sodium carboxymethyl starch; the glidant is micropowder silica gel, talc Any one or more of powder, magnesium stearate.
所述润滑剂为硬脂富马酸钠、硬脂酸镁、微粉硅胶、滑石粉中的至少一种。The lubricant is at least one of sodium stearyl fumarate, magnesium stearate, micronized silica gel and talcum powder.
所述矫味剂为环己基氨基磺酸盐(甜蜜素)、乙酰磺胺酸钾(安赛蜜,A-K糖)、天冬氨酰苯丙氨酸甲酯(阿斯巴甜,甜味素)、天冬酰丙氨酸酰胺(阿力甜)、纽甜、三氯蔗糖、蔗糖、山梨醇、甘露醇、葡萄糖中的任意一种或几种;所述香精为天然香精或人工合成香精,优选地包括牛奶香精、葡萄香精、草莓香精、香兰素、苹果香精、桔子香精、香蕉香精、橙油等天然香精或人工合成香精中的至少一种。Described corrective agent is cyclamate (cyclamate), acesulfame potassium (acesulfame potassium, A-K sugar), aspartame (aspartame, sweetener) , aspartame (alitame), neotame, sucralose, sucrose, sorbitol, mannitol, glucose in any one or more; the flavor is a natural flavor or a synthetic flavor, It preferably includes at least one of milk flavor, grape flavor, strawberry flavor, vanillin, apple flavor, orange flavor, banana flavor, orange oil and other natural or artificial flavors.
所述组合物还包括助流剂,助流剂用量占处方总质量的百分比为0.1~1.0%,所述助流剂为微粉硅胶、滑石粉、硬脂酸镁中的任意一种或几种。The composition also includes a glidant, and the amount of the glidant accounts for 0.1-1.0% of the total mass of the prescription. The glidant is any one or more of micropowder silica gel, talcum powder, and magnesium stearate. .
本发明进一步提出了上述普瑞巴林组合物在制备普瑞巴林片剂上的应用。The present invention further proposes the application of the above pregabalin composition in the preparation of pregabalin tablets.
更进一步地,本发明提出了一种普瑞巴林片剂的制备方法,包括如下步骤:Further, the present invention proposes a preparation method of pregabalin tablet, comprising the steps of:
(1)将各原料药进行门式整粒机整粒,将各原料药进行门式整粒机整粒,整粒后使普瑞巴林为具有方形晶习的普瑞巴林,粒径范围为D90:350~600μm;(1) Carry out the granulation of each raw material drug by a door-type granulator, and carry out granulation of each raw material drug by a door-type granulator. After the granulation, pregabalin is pregabalin with a square crystal habit, and the particle size range is D90: 350~600μm;
(2)将各原辅料除润滑剂外进行混合,过筛,再加入润滑剂混合,得混合颗粒;(2) mixing each raw and auxiliary material except the lubricant, sieving, adding the lubricant and mixing to obtain mixed granules;
(3)将混合颗粒经压片机压制,得硬度为4-6kg的素片。(3) Compress the mixed granules through a tablet machine to obtain plain tablets with a hardness of 4-6kg.
优选地,所述整粒机的筛网孔径为0.8mm,整粒转速为300-700rpm。本发明制备的片剂可以用于治疗癫痫、神经性疼痛的速释制剂。Preferably, the sieve aperture of the granulator is 0.8mm, and the granulation speed is 300-700rpm. The tablet prepared by the invention can be used as an immediate-release preparation for treating epilepsy and neuropathic pain.
有益效果:与现有技术相比,本发明具有如下优点:Beneficial effect: compared with the prior art, the present invention has the following advantages:
(1)本发明经发明人大量的实验和研究,得出:以粒径范围D90为350~600μm、晶习呈方形的普瑞巴林原料药和填充剂、润滑剂及崩解剂复配,可以显著提高物料可压性,并经过简单的混合压片工艺,即可制得质量优良的普瑞巴林口崩片。该速释制剂可实现有效成分普瑞巴林的快速释放,使得口服后较快速达到有效血药浓度;与传统胶囊制剂相比,本发明所制得的速释制剂起效快、吸收快,稳定的效果,口感清凉微
甜、入口即化、口感软糯,无难以忍受苦味,可提高病人的依从性。(1) The present invention has obtained through a large number of experiments and researches by the inventors: the pregabalin bulk drug with a particle size range D90 of 350 to 600 μm and a square crystal habit is compounded with fillers, lubricants and disintegrants, The compressibility of materials can be significantly improved, and pregabalin orally disintegrating tablets of good quality can be prepared through a simple mixing and tableting process. The rapid-release preparation can realize the rapid release of the active ingredient pregabalin, so that the effective blood drug concentration can be reached more quickly after oral administration; compared with the traditional capsule preparation, the prepared rapid-release preparation of the present invention has fast onset of action, fast absorption, and stable The effect, the taste is cool and slightly Sweet, melt-in-the-mouth, soft and glutinous taste, no unbearable bitterness, can improve patient compliance.
(2)本发明所述制备方法,采用门式整粒机对普瑞巴林原料药进行处理,得到特定晶习和一定粒径范围的普瑞巴林原料药,再通过与各种常规辅料混合,以相对简单的工艺,制备一种可压性优良的物料颗粒,用于制备普瑞巴林口崩片。该工艺具有操作简单、控制标准成熟、成本低,产业化程度高等优点;(2) The preparation method of the present invention uses a door-type granulator to process the pregabalin bulk drug to obtain the pregabalin bulk drug with a specific crystal habit and a certain particle size range, and then by mixing with various conventional auxiliary materials, A material granule with excellent compressibility is prepared by a relatively simple process for preparing orally disintegrating pregabalin tablets. The process has the advantages of simple operation, mature control standard, low cost and high degree of industrialization;
(3)本发明通过对参比制剂进行稳定性研究实验发现,脂质辅料的熔点偏低,会影响到稳定性考察过程中产品的质量指标的变化,如外观、有关物质、溶出、硬度等,而且这些价格较高辅料的使用同样会增加产品成本。本发明通过简化辅料种类,控制普瑞巴林原料药的粒径和晶习,达到降低产品成本和制备稳定的普瑞巴林速释制剂的目的。(3) The present invention finds that the melting point of lipid excipients is relatively low by conducting stability research experiments on reference preparations, which will affect the changes in product quality indicators during the stability investigation process, such as appearance, related substances, dissolution, hardness, etc. , and the use of these higher-priced accessories will also increase product costs. The present invention simplifies the types of auxiliary materials and controls the particle size and crystal habit of the pregabalin crude drug, so as to reduce the product cost and prepare the stable pregabalin quick-release preparation.
下面结合附图和具体实施方式对本发明做更进一步的具体说明,本发明的上述和/或其他方面的优点将会变得更加清楚。The advantages of the above and/or other aspects of the present invention will become clearer as the present invention will be further described in detail in conjunction with the accompanying drawings and specific embodiments.
图1为产品1所用原料药显微镜图片;Fig. 1 is the microscopic picture of the bulk drug used in product 1;
图2为产品2所用原料药显微镜图片;Fig. 2 is the microscopic picture of the bulk drug used in product 2;
图3为产品1所用原料药粒度分布图片;Fig. 3 is a picture of the particle size distribution of the bulk drug used in product 1;
图4为产品2所用原料药粒度分布图片;Fig. 4 is the particle size distribution picture of the raw material drug used in product 2;
图5为产品3所用原料药显微镜图片;Fig. 5 is a microscope picture of the raw material drug used in product 3;
图6为产品4所用原料药显微镜图片;Fig. 6 is a microscope picture of the bulk drug used in product 4;
图7为产品5所用原料药显微镜图片;Fig. 7 is a microscope picture of the raw material drug used in product 5;
图8为产品6所用原料药显微镜图片;Fig. 8 is a microscope picture of the bulk drug used in product 6;
图9为产品7所用原料药显微镜图片;Fig. 9 is a microscope picture of the bulk drug used in product 7;
图10为产品1和产品2和参比制剂溶出曲线图片。Figure 10 is a picture of the dissolution curves of Product 1, Product 2 and the reference preparation.
为了更好的理解本发明,下面将通过本发明的实施例和实验数据对本发明及其优势和有益效果。In order to better understand the present invention, the present invention and its advantages and beneficial effects will be discussed through the following examples and experimental data of the present invention.
下述实施例中,产品检测方法如下:In the following examples, the product detection method is as follows:
原料药粒径测定取样方法:
Sampling method for particle size determination of raw materials:
在装有整粒后普瑞巴林原料药的物料袋中,分别从上中下6个不同位置各取样5g,取样后合成一份样品,共计取样30g,送检检测粒度分布。In the material bag containing the granulated pregabalin raw material drug, 5g samples were taken from 6 different positions at the top, middle and bottom respectively. After sampling, a sample was synthesized, and a total of 30g was sampled, which was sent for inspection for particle size distribution.
原料药粒径测定方法:Method for measuring the particle size of raw materials:
原料药粒径测定方法:称量分散剂司盘-85约0.3g于250ml烧杯中,再加入准确量取的120ml正庚烷,得到一定比例的司盘-85正庚烷溶液,置于微量分散器中,搅拌至背景稳定,测量背景信号,再加入0.1g普瑞巴林样品,搅拌60s,得到一定浓度的待检测样品,将样品置于激光粒度仪的微量湿法进样窗口中,并按照相关参数项运行相应的测定方法文件,取3次测定结果算术平均值,即可得原料药粒径数据。Method for measuring the particle size of the raw material: Weigh about 0.3g of the dispersant Span-85 into a 250ml beaker, then add an accurately measured 120ml of n-heptane to obtain a certain proportion of Span-85 n-heptane solution, and place it in a trace In the disperser, stir until the background is stable, measure the background signal, then add 0.1g pregabalin sample, stir for 60s to obtain a certain concentration of the sample to be tested, place the sample in the micro-wet sampling window of the laser particle size analyzer, and Run the corresponding measurement method file according to the relevant parameter items, and take the arithmetic mean value of the three measurement results to obtain the particle size data of the raw material drug.
原料药粒径数据分析:Analysis of raw material particle size data:
粒度分布的含义是用特定的仪器和方法测出粉体样品中不同粒径颗粒占颗粒体积(或个数等)总量的百分数。D10:一个样品的累计(自己加前面或后面所有粒径的百分数),粒度分布数达到10%时所对应的粒径。其物理意义是粒径小于(或大于)它的颗粒占10%。D90:一个样品的累计粒度分布数达到90%时所对应的粒径。其物理意义是粒径小于(或大于)它的颗粒占90%。D50:一个样品的累计粒度分布百分数达到50%时所对应的粒径。其物理意义是粒径大于它的颗粒占50%,小于它的颗粒也占50%,D50也叫中位径或中值粒径。其不表示粉体的平均粒度,表示粉体的平均粒度另有参数,例如D(4,3)、D(3,2)等等。D(4,3)、D(3,2)二者都是以体积为基准表示平均粒径的。其中D(4,3)全称为“质量矩体积平均粒径”简称为体积平均径。其计算方法是将每一个粒径区间两端粒径值进行平均,再与这个区间对应的粒度分布百分数相乘,再将乘积累加,即D(4,3)=f1·D1+f2·D2+f3·D3+…。D(3,2)全称为“体积面积平均粒径”,简称为面积平均径。计算方法是将每一个粒径区间百分数除以它对应的粒径区间的平均值后累加,再求倒数,即D(3,2)=1÷(f1÷D1+f2÷D2+f3÷D3+…)。其中:Di表示第i个粒径区间的平均粒径,fi表示第i个。D(3,2)和D(4,3)之间的关系可以这么理解:对于激光粒度仪来说,越近似圆球型的颗粒,测量的结果就越准确。那么,当D(3,2)和D(4,3)的值越接近,说明样品颗粒的形状越规则,粒度分布越集中。其差值越大,说明样品颗粒的形状越不规则,粒度分布越宽。The meaning of particle size distribution is to use specific instruments and methods to measure the percentage of particles of different particle sizes in the powder sample to the total particle volume (or number, etc.). D10: The accumulation of a sample (add the percentage of all particle sizes in front or behind), the corresponding particle size when the particle size distribution number reaches 10%. Its physical meaning is that the particles whose particle size is smaller (or larger) account for 10%. D90: The particle size corresponding to when the cumulative particle size distribution number of a sample reaches 90%. Its physical meaning is that the particles whose particle size is smaller (or larger) account for 90%. D50: The particle size corresponding to when the cumulative particle size distribution percentage of a sample reaches 50%. Its physical meaning is that the particles with a particle size larger than it account for 50%, and the particles smaller than it also account for 50%. D50 is also called the median diameter or median particle diameter. It does not indicate the average particle size of the powder, but indicates that the average particle size of the powder has other parameters, such as D(4,3), D(3,2) and so on. Both D(4,3) and D(3,2) represent the average particle diameter on the basis of volume. The full name of D(4,3) is "mass moment volume average particle diameter" and is referred to as volume average diameter for short. The calculation method is to average the particle size values at both ends of each particle size range, multiply the particle size distribution percentage corresponding to this range, and then accumulate the products, that is, D(4,3)=f1·D1+f2·D2 +f3·D3+…. The full name of D(3,2) is "volume area average particle diameter", and it is referred to as area average diameter for short. The calculation method is to divide the percentage of each particle size range by the average value of its corresponding particle size range, add up, and then calculate the reciprocal, that is, D(3,2)=1÷(f1÷D1+f2÷D2+f3÷D3+ ...). Among them: Di represents the average particle size of the i-th particle size interval, and fi represents the i-th one. The relationship between D(3,2) and D(4,3) can be understood as follows: for laser particle size analyzers, the closer to spherical particles, the more accurate the measurement results. Then, when the values of D(3,2) and D(4,3) are closer, it means that the shape of the sample particles is more regular and the particle size distribution is more concentrated. The larger the difference, the more irregular the shape of the sample particles and the wider the particle size distribution.
原料药晶习显微镜观察方法:Microscopic observation method of API crystals:
原料药晶习外观通过显微镜进行观察和测量。取普瑞巴林原料药0.01g于载玻片
上,滴加1滴液体石蜡进行分散。显微镜目镜参数为10倍,物镜参数为5倍,观察并拍摄颗粒分散均匀光照充足的照片。The crystal habit appearance of raw materials is observed and measured through a microscope. Take 0.01g of pregabalin bulk drug on the glass slide On, drop 1 drop of liquid paraffin to disperse. The microscope eyepiece parameter is 10 times, and the objective lens parameter is 5 times. Observe and take pictures with uniform dispersion of particles and sufficient light.
流动性、片剂脆碎度、片剂最高硬度测定方法:Determination methods for fluidity, tablet friability and maximum tablet hardness:
取100g总混物料并使用FT-104B休止角测定仪测定物料流动性。取约6.5g成品并使用CJY-300D型片剂脆碎度测定仪进行片剂脆碎度测定。使用YPD-200C型片剂硬度测试仪对成品片剂硬度进行测定。Take 100g of the blended material and use the FT-104B angle of repose tester to measure the fluidity of the material. Take about 6.5g of the finished product and use the CJY-300D tablet friability tester to measure the tablet friability. Use the YPD-200C tablet hardness tester to measure the hardness of the finished tablet.
实施例1Example 1
产品1处方表:
Product 1 Prescription Form:
Product 1 Prescription Form:
产品2处方表:
Product 2 Prescription Form:
Product 2 Prescription Form:
产品1制备工艺流程:Product 1 preparation process:
①将普瑞巴林(D90为900μm、晶习呈长针状和方形)进行门式整粒机整粒,0.8mm整粒筛网,整粒速度为700rpm,整粒后普瑞巴林D90为500μm、晶习呈方形;① Pregabalin (D90 is 900 μm, crystal habit is long needle-shaped and square) is sized by a door-type granulator with a 0.8 mm sieve, and the granulation speed is 700 rpm. After sizing, the D90 of pregabalin is 500 μm , The crystal habit is square;
②按照产品1的处方表中的用量,将微晶纤维素、整粒后普瑞巴林、甘露醇、三氯蔗糖、糖精钠、交联聚维酮SH-SL10、薄荷香精使用方锥混合桶进行混合,混合转速10rpm,混合时间20min;②According to the dosage in the prescription table of product 1, mix microcrystalline cellulose, granulated pregabalin, mannitol, sucralose, sodium saccharin, crospovidone SH-SL10, and mint flavor in a square cone mixing bucket Mixing, mixing speed 10rpm, mixing time 20min;
③在上一步所得混合颗粒过20目震荡筛,过筛后颗粒中再加入硬脂酸镁并使用方锥混合桶进行混合,混合转速10rpm,混合时间20min;③ Pass the mixed granules obtained in the previous step through a 20-mesh vibrating sieve, and then add magnesium stearate to the granules after sieving, and use a square cone mixing barrel for mixing, the mixing speed is 10 rpm, and the mixing time is 20 minutes;
④使用上一步所得混合颗粒进行粉末直接压片。④ Use the mixed granules obtained in the previous step for direct powder compression.
产品2制备工艺流程:Product 2 preparation process:
①按照产品2的处方表中的用量,将普瑞巴林(D90为900μm、晶习呈长针状和方形)、微晶纤维素、甘露醇、三氯蔗糖、糖精钠、交联聚维酮SH-SL10、薄荷香精使用方锥混合桶进行混合,混合转速10rpm,混合时间20min;①According to the dosage in the prescription table of product 2, pregabalin (D90 is 900 μm, crystal habit is long needle-shaped and square), microcrystalline cellulose, mannitol, sucralose, sodium saccharin, crospovidone SH-SL10 and mint essence are mixed in a square cone mixing barrel, the mixing speed is 10rpm, and the mixing time is 20min;
②在上一步所得混合颗粒过20目震荡筛,过筛后颗粒中再加入硬脂酸镁并使用方锥混合桶进行混合,混合转速10rpm,混合时间20min;② Pass the mixed granules obtained in the previous step through a 20-mesh vibrating sieve, and then add magnesium stearate to the granules after sieving and use a square cone mixing barrel for mixing, the mixing speed is 10 rpm, and the mixing time is 20 minutes;
③使用上一步所得混合颗粒进行粉末直接压片。③ Use the mixed granules obtained in the previous step for direct powder compression.
产品1和产品2所用原料药显微镜图片分别如图1和图2所示,产品1和产品2所用原料药粒度分布分别如图3和图4所示。The microscope images of the raw materials used in product 1 and product 2 are shown in Figure 1 and Figure 2, respectively, and the particle size distributions of the raw materials used in product 1 and product 2 are shown in Figure 3 and Figure 4, respectively.
原料药与片剂性质
API and Tablet Properties
API and Tablet Properties
实验结果与结论
Experimental Results and Conclusion
经过门式整粒机整粒后的产品1原料药,其D90为500μm,D(4,3)和D(3,2)差值为74μm。产品2原料药D90为900μm,D(4,3)和D(3,2)差值为575μm。相比产品2,产品1原料药D(3,2)和D(4,3)的差值小,说明产品1原料药颗粒的形状更规则,粒度分布集中,再根据其显微镜照片,表明其晶习为方晶。产品2原料药D(3,2)和D(4,3)的差值大,说明产品2原料药颗粒的形状不规则,粒度分布宽,再根据其显微镜照片,表明其晶习为不均一的方晶和长针状晶体混晶。The D90 of the API of product 1 after being granulated by the portal granulator is 500 μm, and the difference between D(4,3) and D(3,2) is 74 μm. The D90 of product 2 API is 900 μm, and the difference between D(4,3) and D(3,2) is 575 μm. Compared with product 2, the difference between product 1 API D(3,2) and D(4,3) is smaller, indicating that the shape of product 1 API particles is more regular, and the particle size distribution is concentrated. According to its microscopic photos, it shows that its The crystal habit is square crystal. The difference between D(3,2) and D(4,3) of product 2 raw material drug is large, indicating that the shape of product 2 raw material drug particle is irregular and the particle size distribution is wide, and according to its microscopic photo, it shows that its crystal habit is not uniform The square crystal and long needle crystal mixed crystal.
片剂结果表明晶习主要为方晶,D90为500μm的产品1比原料药晶习主要为长针状晶体和方晶混晶的产品2,其物料流动性更好,所压片剂脆碎度更低,最高可压硬度更高。因此,使用晶习主要为方晶的普瑞巴林原料药可以有效提高物料的流动性、可压性,制得性质优良的普瑞巴林口崩片。Tablet results show that the crystal habit is mainly square crystal, and the product 1 whose D90 is 500 μm is more than the product 2 whose crystal habit is mainly long needle-like crystal and square crystal mixed crystal in the raw material medicine, and its material fluidity is better, and the pressed tablet is brittle The degree is lower and the maximum compressive hardness is higher. Therefore, the use of pregabalin raw materials whose crystal habit is mainly fang crystal can effectively improve the fluidity and compressibility of the material, and prepare pregabalin orally disintegrating tablets with excellent properties.
图10为产品1和产品2和参比制剂溶出曲线图。采用0.06M HCL-桨法进行检测,具体检测步骤为:Fig. 10 is the dissolution curve chart of product 1 and product 2 and reference preparation. The 0.06M HCL-paddle method is used for detection, and the specific detection steps are:
溶出介质:0.06M盐酸溶液,配置步骤:量取盐酸5.4ml,用水稀释至1000ml,摇匀,即得。Dissolution medium: 0.06M hydrochloric acid solution, preparation steps: Measure 5.4ml of hydrochloric acid, dilute with water to 1000ml, shake well, and get ready.
对照溶液:取普瑞巴林对照品约16mg,精密称定,置于100mL容量瓶中,加溶出介质溶解并定量稀释至刻度,摇匀(浓度约为160μg/ml)。平行配制两份。Control solution: take about 16 mg of pregabalin reference substance, accurately weigh it, place it in a 100 mL volumetric flask, add dissolution medium to dissolve and quantitatively dilute to the mark, shake well (concentration is about 160 μg/ml). Prepare two copies in parallel.
流动相配制:Mobile phase preparation:
(1)0.04M磷酸氢二铵(pH6.5)(1) 0.04M diammonium hydrogen phosphate (pH6.5)
精密称取磷酸氢二铵5.28g+超纯水,定容至1000ml,用磷酸调节pH值至6.5±0.05,抽滤。Accurately weigh 5.28g of diammonium hydrogen phosphate + ultrapure water, set the volume to 1000ml, adjust the pH value to 6.5±0.05 with phosphoric acid, and filter with suction.
(2)流动相:0.04M磷酸氢二铵(pH6.5):乙腈=90:10(2) Mobile phase: 0.04M diammonium hydrogen phosphate (pH6.5): acetonitrile = 90:10
溶出条件:Dissolution conditions:
溶出介质:0.06M盐酸Dissolution medium: 0.06M hydrochloric acid
溶出装置:桨法Dissolution Apparatus: Paddle Method
转速:50rpmSpeed: 50rpm
溶出介质温度:37±0.5℃Dissolution medium temperature: 37±0.5℃
取样体积、补液体积:取样3.5ml,废液滴弃2ml,不补液。Sampling volume, rehydration volume: sampling 3.5ml, discarding 2ml of waste liquid, no rehydration.
溶出介质体积:900ml。
Dissolution medium volume: 900ml.
投样方式:随机投样。Sampling method: Random sampling.
样品溶液处理:使用0.45μm水系滤头(津腾,聚醚砜,25mm)过滤,弃除初滤液2ml,取续滤液作为样品溶液。Sample solution treatment: use a 0.45 μm water filter head (Jinteng, polyethersulfone, 25mm) to filter, discard 2ml of the initial filtrate, and take the subsequent filtrate as the sample solution.
取样时间点:5、10、15(min)。Sampling time points: 5, 10, 15 (min).
高效液相色谱仪检测条件:High performance liquid chromatography detection conditions:
色谱柱:GL Sciences Inertsil ODS-3V。Column: GL Sciences Inertsil ODS-3V.
比制剂为选用普瑞巴林口崩片,该普瑞巴林于2017年02月17日首次在日本上市,英文商品名LYRICA(乐瑞卡),日文商品名为リリカOD锭,持证商为Pfizer Japan Inc.(ファイザー株式会社),本申请中将参比制剂标记为EA6596。从结果中可以看出,本发明产品的溶出曲线与参比制剂相似,体外结果在一定程度上说明本发明产品与参比制剂一样起效快,吸收快。The preparation is pregabalin orally disintegrating tablets. The pregabalin was first listed in Japan on February 17, 2017. The English product name is LYRICA (Lerica), and the Japanese product name is リリカOD Tablet. The licensee is Pfizer Japan Inc. (ファイザー Co., Ltd.), the reference preparation is marked as EA6596 in this application. As can be seen from the results, the stripping curve of the product of the present invention is similar to that of the reference preparation, and the in vitro results illustrate to a certain extent that the product of the present invention has the same rapid onset and absorption as the reference preparation.
实施例2Example 2
产品3处方表:
Product 3 Prescription Form:
Product 3 Prescription Form:
产品3制备工艺流程:Product 3 preparation process:
①将普瑞巴林(D90为900μm、晶习呈长针状和方形)进行门式整粒机整粒,0.8mm整粒筛网,整粒速度由700rpm降低为设备最低转速的300rpm,整粒后普瑞巴林D90为550μm、晶习呈方形;
① Pregabalin (D90 is 900 μm, crystal habit is long needle-shaped and square) is sized by a door-type granulator with a 0.8mm sieve, and the granulation speed is reduced from 700rpm to 300rpm, which is the lowest speed of the equipment. The D90 of pregabalin is 550 μm, and the crystal habit is square;
②按照产品3处方表中的用量,将微晶纤维素、整粒后普瑞巴林、甘露醇、三氯蔗糖、糖精钠、交联聚维酮SH-SL10、薄荷香精使用方锥混合桶进行混合,混合转速10rpm,混合时间20min;②According to the dosage in the prescription table of product 3, mix microcrystalline cellulose, granulated pregabalin, mannitol, sucralose, sodium saccharin, crospovidone SH-SL10, and mint essence in a square cone mixing bucket. Mixing, mixing speed 10rpm, mixing time 20min;
③在上一步所得混合颗粒过20目震荡筛,过筛后颗粒中再加入硬脂酸镁并使用方锥混合桶进行混合,混合转速10rpm,混合时间20min;③ Pass the mixed granules obtained in the previous step through a 20-mesh vibrating sieve, and then add magnesium stearate to the granules after sieving, and use a square cone mixing barrel for mixing, the mixing speed is 10 rpm, and the mixing time is 20 minutes;
④使用上一步所得混合颗粒进行粉末直接压片。④ Use the mixed granules obtained in the previous step for direct powder compression.
产品3所用原料药显微镜图片如图5所示。The microscope picture of the API used in product 3 is shown in Figure 5.
原料药与片剂性质
API and Tablet Properties
API and Tablet Properties
实验结果与结论Experimental Results and Conclusion
将门式整粒机转速由700rpm降低至300rpm,与700rpm整粒转速所得原料药相比,300rpm整粒转速所得原料药的D90,D(4,3)和D(3,2)的差值无明显变化。片剂结果表明,与700rpm整粒转速所得原料药的产品1相比,300rpm整粒转速所得原料药的产品3的物料流动性、所压片剂脆碎度、最高可压硬度也无明显差异。因此,工艺生产后续应使用生产效率更高的700rpm作为门式整粒机的整粒转速参数,该操作简单、容易控制。The door-type granulator speed is reduced from 700rpm to 300rpm, compared with the bulk drug obtained at the 700rpm granulation speed, the D90 of the raw material drug obtained at the 300rpm granulation speed, the difference between D (4, 3) and D (3, 2) has no difference. obvious change. Tablet results show that, compared with product 1 obtained by granulating at 700rpm, there is no significant difference in material fluidity, friability and maximum compressible hardness of product 3 obtained at 300rpm. . Therefore, 700rpm, which has higher production efficiency, should be used as the granulation speed parameter of the gantry granulator in the subsequent production process, which is simple and easy to control.
实施例3Example 3
产品4处方表:
Product 4 Prescription Form:
Product 4 Prescription Form:
产品4制备工艺流程:Product 4 preparation process:
①将普瑞巴林(D90为900μm、晶习呈长针状和方形)进行门式整粒机整粒,0.8mm整粒筛网改为0.9mm筛网,整粒速度为700rpm,整粒后普瑞巴林D90为700μm、晶习呈长针状和方形。① Pregabalin (D90 is 900 μm, crystal habit is long needle-shaped and square) is sized by a door-type granulator, the 0.8mm sieve is changed to a 0.9mm sieve, and the sizing speed is 700rpm. After sizing, The D90 of pregabalin is 700 μm, and the crystal habit is long needle-shaped and square.
②按照产品4处方表中的用量将微晶纤维素、整粒后普瑞巴林、甘露醇、三氯蔗糖、糖精钠、交联聚维酮SH-SL10、薄荷香精使用方锥混合桶进行混合,混合转速10rpm,混合时间20min;②Mix the microcrystalline cellulose, granulated pregabalin, mannitol, sucralose, sodium saccharin, crospovidone SH-SL10, and mint essence in a square cone mixing barrel according to the dosage in the product 4 prescription table , mixing speed 10rpm, mixing time 20min;
③在上一步所得混合颗粒过20目震荡筛,过筛后颗粒中再加入硬脂酸镁并使用方锥混合桶进行混合,混合转速10rpm,混合时间20min;③ Pass the mixed granules obtained in the previous step through a 20-mesh vibrating sieve, and then add magnesium stearate to the granules after sieving, and use a square cone mixing barrel for mixing, the mixing speed is 10 rpm, and the mixing time is 20 minutes;
④使用上一步所得混合颗粒进行粉末直接压片。④ Use the mixed granules obtained in the previous step for direct powder compression.
产品4所用原料药显微镜图片如图6所示。The microscope picture of the API used in product 4 is shown in Figure 6.
原料药与片剂性质
API and Tablet Properties
API and Tablet Properties
实验结果与结论Experimental Results and Conclusion
将门式整粒机整粒筛网0.8mm替换为0.9mm筛网,与0.8mm筛网整粒所得原料药相比,0.9mm筛网整粒所得原料药的D90,D(4,3)和D(3,2)的差值均明显增大。结合原料药显微镜图片,表明0.9mm筛网整粒所得普瑞巴林原料药为长针状晶体和方晶混晶,不如0.8mm筛网整粒所得原料药圆整,并且整体粒径偏大,D90为700μm。
片剂结果表明,与0.8mm筛网整粒所得原料药的产品1相比,0.9mm筛网整粒所得原料药的产品4的物料流动性减慢、所压片剂脆碎度变高、最高可压硬度下降,崩解时限变慢。因此,工艺生产后续应使用0.8mm筛网作为门式整粒机的筛网参数,该操作简单、容易控制,产品质量可以得到保证。Replace the 0.8mm sieve mesh of the gate granulator with a 0.9mm sieve, compared with the bulk drug obtained by 0.9mm sieve sizing, the D90, D (4, 3) and The differences of D(3, 2) all increased significantly. Combined with the microscope pictures of the raw material drug, it shows that the pregabalin raw material drug obtained by 0.9mm sieve granulation is long needle-shaped crystal and square crystal mixed crystal, which is not as round as the raw material drug obtained by 0.8mm sieve granulation, and the overall particle size is too large. D90 is 700 μm. Tablet results show that compared with the product 1 of the raw material drug obtained by 0.8 mm sieve granulation, the material fluidity of product 4 of the raw material drug obtained by 0.9 mm sieve granulation slows down, and the friability of the pressed tablet becomes higher. The maximum compressible hardness decreased, and the disintegration time became slower. Therefore, the 0.8mm screen should be used as the screen parameter of the portal granulator in the subsequent production process. The operation is simple and easy to control, and the product quality can be guaranteed.
实施例4Example 4
产品5处方表:
Product 5 Prescription Form:
Product 5 Prescription Form:
产品5制备工艺流程:Product 5 preparation process:
①将普瑞巴林(D90为900μm、晶习呈长针状和方形)进行门式整粒机整粒,0.8mm整粒筛网改为0.7mm筛网,整粒速度为700rpm,整粒后普瑞巴林D90为350μm、晶习呈方形;① Pregabalin (D90 is 900 μm, crystal habit is long needle-shaped and square) is sized by a door-type granulator, the 0.8mm granulation screen is changed to a 0.7mm sieve, and the granulation speed is 700rpm. Pregabalin D90 is 350 μm, and the crystal habit is square;
②按照产品5处方表中的用量,将微晶纤维素、整粒后普瑞巴林、甘露醇、三氯蔗糖、糖精钠、交联聚维酮SH-SL10、薄荷香精使用方锥混合桶进行混合,混合转速10rpm,混合时间20min;②According to the dosage in the prescription table of product 5, mix microcrystalline cellulose, granulated pregabalin, mannitol, sucralose, sodium saccharin, crospovidone SH-SL10, and mint essence in a square cone mixing bucket Mixing, mixing speed 10rpm, mixing time 20min;
③在上一步所得混合颗粒过20目震荡筛,过筛后颗粒中再加入硬脂酸镁并使用方锥混合桶进行混合,混合转速10rpm,混合时间20min;③ Pass the mixed granules obtained in the previous step through a 20-mesh vibrating sieve, and then add magnesium stearate to the granules after sieving, and use a square cone mixing barrel for mixing, the mixing speed is 10 rpm, and the mixing time is 20 minutes;
④使用上一步所得混合颗粒进行粉末直接压片。④ Use the mixed granules obtained in the previous step for direct powder compression.
产品5所用原料药显微镜图片如图7所示。
The microscope picture of the API used in product 5 is shown in Figure 7.
原料药与片剂性质
API and Tablet Properties
API and Tablet Properties
实验结果与结论Experimental Results and Conclusion
将门式整粒机整粒筛网0.8mm替换为0.7mm筛网,与0.8mm筛网整粒所得原料药相比,0.7mm筛网整粒所得原料药的D(4,3)和D(3,2)的差值无明显变化,但D90明显变小,整体粒径明显变小。结合原料药显微镜图片,表明0.7mm筛网整粒所得普瑞巴林原料药为方晶,较为圆整,但整体粒径偏小,D90为350μm。片剂结果表明,与0.8mm筛网整粒所得原料药的产品1相比,0.7mm筛网整粒所得原料药的产品5的物料流动性无明显变化、所压片剂脆碎度稍有增加、最高可压硬度稍有下降,崩解时限明显变慢,推测为原料药细粉较多,崩解时容易粘附于崩解仪筛网上,无法顺利通过,导致崩解时限较长。因此,工艺生产后续应使用0.8mm筛网作为门式整粒机的筛网参数,该操作简单、容易控制,产品质量可以得到保证。Replace the 0.8mm sieve mesh of the portal granulator with a 0.7mm sieve, compared with the raw material medicine obtained by 0.8mm sieve sizing, the D(4, 3) and D( 3, 2) The difference has no obvious change, but the D90 is obviously smaller, and the overall particle size is obviously smaller. Combined with the microscope pictures of the raw material drug, it shows that the pregabalin raw material drug obtained by 0.7mm sieve granulation is a square crystal, which is relatively round, but the overall particle size is relatively small, and the D90 is 350 μm. Tablet results show that compared with Product 1 of the bulk drug obtained through 0.8 mm sieve granulation, the material fluidity of Product 5 of the bulk drug obtained through 0.7 mm sieve granulation has no significant change, and the friability of the pressed tablet is slightly reduced. increased, the maximum compressible hardness decreased slightly, and the disintegration time limit was significantly slower. It is speculated that there are more fine powders of raw materials, which tend to adhere to the disintegration instrument screen during disintegration and cannot pass through smoothly, resulting in a longer disintegration time limit. Therefore, the 0.8mm screen should be used as the screen parameter of the portal granulator in the subsequent production process. The operation is simple and easy to control, and the product quality can be guaranteed.
实施例5Example 5
产品6处方表:
Product 6 Prescription Form:
Product 6 Prescription Form:
产品6制备工艺流程:Product 6 preparation process:
①将普瑞巴林(D90为900μm、晶习呈长针状和方形)进行中药粉碎机粉碎,粉碎时间为4s,得到的粉碎后普瑞巴林D90为200μm、晶习呈方形;① Pulverize pregabalin (with a D90 of 900 μm and a long needle-like crystal habit and a square shape) in a traditional Chinese medicine pulverizer for 4 s, and the obtained pregabalin has a D90 of 200 μm and a square crystal habit;
②按照产品6处方表中的用量将微晶纤维素、粉碎后普瑞巴林、甘露醇、三氯蔗糖、糖精钠、交联聚维酮SH-SL10、薄荷香精使用方锥混合桶进行混合,混合转速10rpm,混合时间20min;② Mix microcrystalline cellulose, pulverized pregabalin, mannitol, sucralose, sodium saccharin, crospovidone SH-SL10, and mint essence in a square cone mixing barrel according to the dosage in the product 6 prescription table. Mixing speed 10rpm, mixing time 20min;
③在上一步所得混合颗粒过20目震荡筛,过筛后颗粒中再加入硬脂酸镁并使用方锥混合桶进行混合,混合转速10rpm,混合时间20min;③ Pass the mixed granules obtained in the previous step through a 20-mesh vibrating sieve, and then add magnesium stearate to the granules after sieving, and use a square cone mixing barrel for mixing, the mixing speed is 10 rpm, and the mixing time is 20 minutes;
④使用上一步所得混合颗粒进行粉末直接压片。④ Use the mixed granules obtained in the previous step for direct powder compression.
原料药粒径测定取样方法Sampling method for particle size determination of raw materials
在装有中药粉碎后普瑞巴林原料药的物料袋中,分别从上中下6个不同位置各取样5g,取样后合成一份样品,共计取样30g,送检检测粒度分布。In the material bag containing the pregabalin crude drug after crushing the traditional Chinese medicine, 5g samples were taken from 6 different positions at the top, middle and bottom respectively. After sampling, a sample was synthesized, and a total of 30g was sampled, which was sent for inspection for particle size distribution.
产品6所用原料药显微镜图片如图8所示。The microscope picture of the API used in Product 6 is shown in Figure 8.
原料药与片剂性质
API and Tablet Properties
API and Tablet Properties
实验结果与结论Experimental Results and Conclusion
将门式整粒机整粒工序变更为中药粉碎机粉碎,与0.8mm筛网整粒所得原料药相比,中药粉碎机粉碎4s所得原料药的D(4,3)和D(3,2)的差值更小,且D90明显变更小,整体粒径明显变小。结合原料药显微镜图片,表明中药粉碎机粉碎所得普瑞巴林原料药为方晶,比较圆整,但整体粒径偏小,D90为200μm。片剂结果表明,与0.8mm筛网整粒所得原料药的产品1相比,中药粉碎机粉碎4s所得原料药的产品6的物料流动性稍微下降、所压片剂脆碎度明显增加、最高可压硬度明显下降,崩解时限明显变
更慢,推测为原料药细粉较多,崩解时容易粘附于崩解仪筛网上,无法顺利通过,导致崩解时限较长。因此,中药粉碎工艺难以替代门式整粒工序,中药粉碎工艺粉碎效果较难控制,控制标准难以确定,无法得到具有特定晶习和一定粒径范围的普瑞巴林原料药,不能制备质量合格的普瑞巴林口崩片。The granulation process of the portal granulator was changed to pulverization by the traditional Chinese medicine pulverizer. Compared with the raw material medicine obtained by 0.8mm sieve granulation, the D (4, 3) and D (3, 2) of the raw material medicine obtained by pulverizing the traditional Chinese medicine pulverizer for 4 seconds The difference is smaller, and the D90 is significantly smaller, and the overall particle size is significantly smaller. Combined with the microscope pictures of the raw material drug, it shows that the pregabalin raw material drug obtained by pulverizing the traditional Chinese medicine pulverizer is a square crystal, which is relatively round, but the overall particle size is relatively small, and the D90 is 200 μm. Tablet results show that, compared with product 1 of the raw material drug obtained by 0.8mm sieve granulation, the material fluidity of product 6 of the raw material drug obtained by pulverizing the traditional Chinese medicine pulverizer for 4 seconds is slightly reduced, and the friability of the pressed tablet is significantly increased, the highest The compressible hardness decreased significantly, and the disintegration time limit changed significantly. Slower, it is speculated that there are more fine powders of raw materials, which tend to adhere to the screen of the disintegration instrument during disintegration, and cannot pass through smoothly, resulting in a longer disintegration time limit. Therefore, it is difficult for traditional Chinese medicine pulverization process to replace the door-type granulation process. The pulverization effect of traditional Chinese medicine pulverization process is difficult to control, and the control standard is difficult to determine. Oral disintegration of pregabalin.
实施例6Example 6
产品7处方表:
Product 7 Prescription Form:
Product 7 Prescription Form:
产品7制备工艺流程:Product 7 preparation process:
①将普瑞巴林(D90为900μm、晶习呈长针状和方形)进行万能粉碎机粉碎,粉碎筛网为0.8mm,粉碎转速为设备最低转速1500rpm,粉碎后普瑞巴林D90为250μm、晶习呈方形;① Pulverize pregabalin (D90 is 900 μm, and the crystal habit is long needle-shaped and square) in a universal pulverizer. habit of square;
②按照产品7处方表中的用量将微晶纤维素、粉碎后普瑞巴林、甘露醇、三氯蔗糖、糖精钠、交联聚维酮SH-SL10、薄荷香精使用方锥混合桶进行混合,混合转速10rpm,混合时间20min;② Mix microcrystalline cellulose, pulverized pregabalin, mannitol, sucralose, sodium saccharin, crospovidone SH-SL10, and mint essence in a square cone mixing tank according to the dosage in the product 7 prescription table, Mixing speed 10rpm, mixing time 20min;
③在上一步所得混合颗粒过20目震荡筛,过筛后颗粒中再加入硬脂酸镁并使用方锥混合桶进行混合,混合转速10rpm,混合时间20min;③ Pass the mixed granules obtained in the previous step through a 20-mesh vibrating sieve, and then add magnesium stearate to the granules after sieving, and use a square cone mixing barrel for mixing, the mixing speed is 10 rpm, and the mixing time is 20 minutes;
④使用上一步所得混合颗粒进行粉末直接压片。④ Use the mixed granules obtained in the previous step for direct powder compression.
原料药粒径测定取样方法
Sampling method for particle size determination of raw materials
在装有万能粉碎后普瑞巴林原料药的物料袋中,分别从上中下6个不同位置各取样5g,取样后合成一份样品,共计取样30g,送检检测粒度分布。In the material bag containing the pregabalin raw material after universal crushing, 5g samples were taken from 6 different positions at the top, middle and bottom respectively. After sampling, a sample was synthesized, and a total of 30g was sampled, which was sent for inspection for particle size distribution.
产品7所用原料药显微镜图片如图9所示。The microscope picture of the API used in Product 7 is shown in Figure 9.
原料药与片剂性质
API and Tablet Properties
API and Tablet Properties
实验结果与结论Experimental Results and Conclusion
将门式整粒机整粒工序变更为万能粉碎机粉碎,与0.8mm筛网门式整粒机整粒所得原料药相比,万能粉碎机粉碎所得原料药的D(4,3)和D(3,2)的差值更小,且D90明显变更小,整体粒径明显变小。结合原料药显微镜图片,表明万能粉碎机粉碎所得普瑞巴林原料药为方晶,比较圆整,但整体粒径偏小,D90为250μm。片剂结果表明,与0.8mm筛网整粒所得原料药的产品1相比,万能粉碎机粉碎所得原料药的产品7的物料流动性稍微下降、所压片剂脆碎度稍有增加、最高可压硬度稍有下降,崩解时限明显变更慢。因此,万能粉碎工艺也难以替代门式整粒工序,万能工艺粉碎效果也较难控制,控制标准难以确定,无法得到具有特定晶习和一定粒径范围的普瑞巴林原料药,不能制备质量合格的普瑞巴林口崩片。The granulation process of the portal granulator is changed to the pulverization of the universal pulverizer. Compared with the raw material medicine obtained by the 0.8mm screen gantry granulator, the D (4, 3) and D ( 3, 2) The difference is smaller, and the D90 is significantly smaller, and the overall particle size is significantly smaller. Combined with the microscope pictures of the raw material drug, it shows that the pregabalin raw material drug obtained by pulverizing with a universal pulverizer is a square crystal, which is relatively round, but the overall particle size is relatively small, and the D90 is 250 μm. Tablet results show that compared with the product 1 of the raw material drug obtained by 0.8mm sieve granulation, the material fluidity of the product 7 of the raw material drug obtained by pulverizing the universal pulverizer slightly decreases, and the friability of the pressed tablet increases slightly, the highest The compressible hardness decreased slightly, and the disintegration time was significantly slower. Therefore, it is also difficult for the universal pulverization process to replace the door-type granulation process. The pulverization effect of the universal process is also difficult to control, and the control standards are difficult to determine. It is impossible to obtain pregabalin raw materials with specific crystal habits and a certain particle size range, and the preparation quality is not qualified. orally disintegrating pregabalin tablets.
实施例7Example 7
产品8处方表:
Product 8 Prescription Form:
Product 8 Prescription Form:
产品8制备工艺流程:Product 8 preparation process:
①按照产品8处方表,将甘露醇溶于水中,并搅拌均匀,配制成甘露醇溶液;① Dissolve mannitol in water according to the prescription table of product 8, and stir evenly to prepare mannitol solution;
②将微晶纤维素、普瑞巴林、三氯蔗糖、糖精钠、交联聚维酮SH-SL10、薄荷香精于高剪切制粒锅中进行混合,剪切转速500rpm,搅拌转速200rpm,混合时间10min;②Mix microcrystalline cellulose, pregabalin, sucralose, sodium saccharin, crospovidone SH-SL10, and mint essence in a high-shear granulator, with a shear speed of 500 rpm and a stirring speed of 200 rpm, and mix Time 10min;
③将甘露醇溶液以15g/s的喷液速度、雾化压力为0.08MPa,喷入高剪切制粒锅中进行制粒,剪切转速1500rpm,搅拌转速500rpm,制粒时间为3min;③Spray the mannitol solution into a high-shear granulation pot with a spray speed of 15g/s and an atomization pressure of 0.08MPa for granulation. The shear speed is 1500rpm, the stirring speed is 500rpm, and the granulation time is 3min;
④将所制得颗粒进行8*8mm湿整粒,再于流化床中,干燥温度45℃,流化风速为60m3/h进行干燥,所得干燥颗粒再进行0.8mm筛网门式整粒,整粒转速700rpm;④The prepared granules are subjected to 8*8mm wet granulation, and then dried in a fluidized bed at a drying temperature of 45°C and a fluidization wind speed of 60m 3 /h, and the obtained dried granules are then subjected to 0.8mm sieve gate type granulation , the rotation speed of the whole grain is 700rpm;
⑤整粒后颗粒中再加入硬脂酸镁并使用方锥混合桶进行混合,混合转速10rpm,混合时间20min;⑤After granulation, add magnesium stearate to the granules and use a square cone mixing barrel for mixing, the mixing speed is 10rpm, and the mixing time is 20min;
⑥使用上一步所得混合颗粒进行压片。⑥Use the mixed granules obtained in the previous step for tablet compression.
片剂性质
Tablet properties
Tablet properties
片剂口感评价
Tablet taste evaluation
Tablet taste evaluation
实验结果与结论Experimental Results and Conclusion
将粉末直接压片工序整体变更为高剪切制粒压片,片剂结果表明,与粉末直接压片所得普瑞巴林口崩片产品1相比,高剪切制粒压片所得普瑞巴林口崩片产品8的物料流动性变化不大、所压片剂脆碎度变化不大、最高可压硬度稍有下降,并且崩解时限明显变更慢,推测为高剪切制粒后原料药颗粒被包裹覆盖,崩解时不容易溶出散开,导致物料颗粒粘附于崩解仪筛网上,无法顺利通过,导致崩解时限较长。在4位评价人的片剂口感评价结果中,不同工艺的产品导致的味道无明显差别,但4位评价人对产品8的口感评价中均体现了口感不佳,有细颗粒等感觉,整体而言,粉末直接压片的产品1口感更胜一筹。因此,高剪切制粒压片工艺不适用于普瑞巴林口崩片的制备,高剪切制粒压片工艺也较为繁琐,生产效率较低,控制标准难以确定,不易制得质量合格的普瑞巴林口崩片。The overall powder direct compression process was changed to high-shear granulation tablet compression. Tablet results showed that compared with the pregabalin orally disintegrating tablet product 1 obtained by powder direct compression, the pregabalin obtained by high-shear granulation Orally disintegrating tablet product 8 has little change in material fluidity, little change in the friability of the compressed tablet, a slight decrease in the maximum compressible hardness, and a significantly slower disintegration time limit, which is presumed to be the raw material medicine after high-shear granulation The particles are wrapped and covered, and it is not easy to dissolve and disperse during disintegration, which causes the material particles to adhere to the screen of the disintegration instrument and cannot pass through smoothly, resulting in a longer disintegration time limit. In the tablet mouthfeel evaluation results of the 4 evaluators, there was no significant difference in the taste caused by the products of different processes, but the taste evaluation of the product 8 by the 4 evaluators all reflected that the mouthfeel was not good, there were fine grains, etc., and the overall In terms of taste, the taste of product 1 directly compressed by powder is better. Therefore, the high-shear granulation tableting process is not suitable for the preparation of pregabalin mouth-disintegrating tablets. The high-shear granulation tableting process is also relatively cumbersome, the production efficiency is low, the control standard is difficult to determine, and it is difficult to obtain qualified quality tablets. Oral disintegration of pregabalin.
实施例8Example 8
产品9处方表:
Product 9 Prescription Form:
Product 9 Prescription Form:
产品9制备工艺流程:Product 9 preparation process:
①按照产品9处方表,将甘露醇溶于水中,并搅拌均匀,配制成甘露醇溶液;① Dissolve mannitol in water according to product 9 prescription table, and stir evenly to make mannitol solution;
②将普瑞巴林(D90为900μm、晶习呈长针状和方形)进行门式整粒机整粒,0.8mm整粒筛网,整粒速度为700rpm。② Pregabalin (D90 is 900 μm, crystal habit is long needle-shaped and square) is sized by a portal granulator with a 0.8mm sieve at a sizing speed of 700rpm.
③将微晶纤维素、整粒后普瑞巴林、三氯蔗糖、糖精钠、交联聚维酮SH-SL10、薄荷香精于高剪切制粒锅中进行混合,剪切转速500rpm,搅拌转速200rpm,混合时间10min;③Mix microcrystalline cellulose, pregabalin after granulation, sucralose, sodium saccharin, crospovidone SH-SL10, and mint essence in a high-shear granulator, with a shearing speed of 500 rpm and a stirring speed of 500 rpm. 200rpm, mixing time 10min;
④将甘露醇溶液以15g/s的喷液速度、雾化压力为0.08MPa,喷入高剪切制粒锅中进行制粒,剪切转速1500rpm,搅拌转速500rpm,制粒时间为3min;④ Spray the mannitol solution into a high-shear granulation pot with a spray speed of 15g/s and an atomization pressure of 0.08MPa for granulation. The shear speed is 1500rpm, the stirring speed is 500rpm, and the granulation time is 3min;
⑤将所制得颗粒进行8*8mm湿整粒,再于流化床中,干燥温度45℃,流化风速为60m3/h进行干燥,所得干燥颗粒再进行0.8mm筛网门式整粒,整粒转速700rpm;⑤The prepared granules are subjected to 8*8mm wet granulation, and then dried in a fluidized bed at a drying temperature of 45°C and a fluidization wind speed of 60m 3 /h, and the obtained dried granules are then subjected to 0.8mm sieve gate type granulation , the rotation speed of the whole grain is 700rpm;
⑥整粒后颗粒中再加入硬脂酸镁并使用方锥混合桶进行混合,混合转速10rpm,混合时间20min;⑥After granulation, add magnesium stearate to the granules and use a square cone mixing barrel for mixing, the mixing speed is 10rpm, and the mixing time is 20min;
⑦使用上一步所得混合颗粒进行压片。⑦Use the mixed granules obtained in the previous step for tablet compression.
片剂性质
Tablet properties
Tablet properties
实验结果与结论Experimental Results and Conclusion
将粉末直接压片工序整体变更为先对原料药进行门式整粒再进行高剪切制粒压片,片剂结果表明,与粉末直接压片所得普瑞巴林口崩片产品1相比,先对原料药进行门式整粒再进行高剪切制粒压片所得普瑞巴林口崩片产品9的物料流动性变化不大、所压片剂脆碎度变化不大、最高可压硬度变化不大,但崩解时限仍旧较慢,推测为高剪切制粒后,经过门式整粒后原料药颗粒被包裹覆盖,崩解时依旧不容易溶出散开,导致物料颗粒粘附于崩解仪筛网上,无法顺利通过,导致崩解时限较长。因此,粉末直接压片工艺更加适用于普瑞巴林口崩片的制备并且高剪切制粒压片工艺也较为繁琐,生产效率较低,控制标准难以确定,不易制得质量合格的普瑞巴林口崩片。The powder direct compression process was changed as a whole to gate-type granulation of the raw material drug first, and then high-shear granulation and tablet compression. The tablet results showed that compared with the pregabalin orally disintegrating tablet product 1 obtained by powder direct compression, The material fluidity of the pregabalin mouth-disintegrating tablet product 9 obtained by gate-type granulation of the raw material drug and then high-shear granulation and tablet compression did not change much, the friability of the compressed tablet did not change much, and the highest compressible hardness There is little change, but the disintegration time limit is still relatively slow. It is speculated that after high-shear granulation, the raw material drug particles are covered after gate-type granulation. The disintegration instrument screen cannot pass through smoothly, resulting in a longer disintegration time limit. Therefore, the powder direct compression process is more suitable for the preparation of pregabalin orally disintegrating tablets, and the high-shear granulation tableting process is also relatively cumbersome, the production efficiency is low, the control standard is difficult to determine, and it is difficult to obtain qualified pregabalin Mouth disintegration.
总结Summarize
目前市面上常见在售普瑞巴林原料药粒径大小范围均约为800~1100微米,晶习为长针状和方晶混晶。这种普瑞巴林原料药可压性和流动性较差,无法用于普瑞巴林口崩片的制备。通过门式整粒机整粒,整粒筛网为0.8mm,整粒转速为700rpm,可以高效且易控地制备粒径大小范围为350~600μm、D(4,3)和D(3,2)的差值范围较小,为50~150μm、晶习为方形的普瑞巴林原料药,该原料药可以有效改善目前市面上常见在售普瑞巴林原料药的流动性和可压性,达到生产工艺操作简单、控制标准成熟、成本低,产业化程度高、制得质量优良的普瑞巴林口崩片目的。综上,本发明提供了另一种思路,通过制备一定粒径范围和特定晶习形态的普瑞巴林原料药,与普通的普瑞巴林原料药相比,制备的总混物料的可压性明显提高,并且制备总混物料过程中没有使用额外的昂贵辅料。At present, the particle size range of common pregabalin raw materials sold in the market is about 800-1100 microns, and the crystal habit is elongated needle-shaped and square crystal mixed crystal. This pregabalin crude drug has poor compressibility and fluidity, and cannot be used for the preparation of pregabalin orally disintegrating tablets. The granulation is sized by a door-type granulator, the size of the sieve is 0.8mm, and the granulation speed is 700rpm, which can efficiently and easily control the preparation of particle sizes ranging from 350 to 600μm, D(4,3) and D(3, 2) The range of the difference is small, 50-150 μm, pregabalin API with square crystal habit, this API can effectively improve the fluidity and compressibility of common pregabalin APIs currently on the market, The purpose of producing pregabalin orally disintegrating tablets with simple operation, mature control standards, low cost, high industrialization degree and excellent quality is achieved. In summary, the present invention provides another way of thinking, by preparing pregabalin raw materials with a certain particle size range and specific crystal habit, compared with ordinary pregabalin raw materials, the compressibility of the prepared blended materials Significantly improved, and no additional costly excipients are used in the preparation of the blend.
本发明的方法已经通过较佳实施例进行了描述,相关人员明显能在本发明内容、精神和范围内对本文所述的方法和应用进行改动或适当变更与组合,来实现和应用本发明技术。本领域技术人员可以借鉴本文内容,适当改进工艺参数实现。特别需要指出的是,所有类似的替换和改动对本领域技术人员来说是显而易见的,它们都被视为包括在本发明内。
The method of the present invention has been described through preferred embodiments, and relevant persons can obviously make changes or appropriate changes and combinations to the methods and applications described herein within the content, spirit and scope of the present invention to realize and apply the technology of the present invention . Those skilled in the art can refer to the content of this article to appropriately improve the process parameters to achieve. In particular, it should be pointed out that all similar substitutions and modifications are obvious to those skilled in the art, and they are all considered to be included in the present invention.
Claims (10)
- 一种适用于粉末压片的普瑞巴林组合物,其特征在于,其活性组分普瑞巴林为具有方形晶习的普瑞巴林,粒径范围为D90:350~600μm,用量占处方总重量的20%-50%。A pregabalin composition suitable for powder compression, characterized in that the active component pregabalin is pregabalin with a square crystal habit, the particle size range is D90: 350-600 μm, and the dosage accounts for the total weight of the prescription 20%-50% of.
- 根据权利要求1所述的普瑞巴林组合物,其特征在于,所述普瑞巴林组合物还包括填充剂、崩解剂、矫味剂、香精和润滑剂。The pregabalin composition according to claim 1, wherein the pregabalin composition also includes a filler, a disintegrating agent, a flavoring agent, an essence and a lubricant.
- 根据权利要求2所述的普瑞巴林组合物,其特征在于,所述填充剂用量为0.0%~80.0%,矫味剂0.1%~15.0%,崩解剂1.0%~20.0%,润滑剂0.5%~3.0%,上述百分比均为占处方总质量的百分比。The pregabalin composition according to claim 2, wherein the dosage of the filler is 0.0% to 80.0%, the flavoring agent is 0.1% to 15.0%, the disintegrant is 1.0% to 20.0%, and the lubricant is 0.5%. %~3.0%, the above percentages are the percentages of the total weight of the prescription.
- 根据权利要求2所述的普瑞巴林组合物,其特征在于,所述填充剂为纤维素衍生物和淀粉衍生物中的任意一种或两种。The pregabalin composition according to claim 2, wherein the filler is any one or both of cellulose derivatives and starch derivatives.
- 根据权利要求2所述的普瑞巴林组合物,其特征在于,所述崩解剂为交联羧甲基纤维素钠、交联聚维酮、低取代羟丙基纤维素或羧甲基淀粉钠中的至少一种。The pregabalin composition according to claim 2, wherein the disintegrant is croscarmellose sodium, crospovidone, low-substituted hydroxypropyl cellulose or carboxymethyl starch at least one of sodium.
- 根据权利要求2所述的普瑞巴林组合物,其特征在于,所述润滑剂为硬脂富马酸钠、硬脂酸镁、微粉硅胶、滑石粉中的至少一种。The pregabalin composition according to claim 2, wherein the lubricant is at least one of sodium stearyl fumarate, magnesium stearate, micronized silica gel, and talcum powder.
- 根据权利要求2所述的普瑞巴林组合物,其特征在于,所述矫味剂为环己基氨基磺酸盐、乙酰磺胺酸钾、天冬氨酰苯丙氨酸甲酯、天冬酰丙氨酸酰胺、纽甜、三氯蔗糖、蔗糖、山梨醇、甘露醇、葡萄糖中的任意一种或几种;所述香精为天然香精或人工合成香精。The pregabalin composition according to claim 2, wherein the flavoring agent is cyclamate, acesulfame potassium, aspartame, aspartame Any one or more of amino acid amide, neotame, sucralose, sucrose, sorbitol, mannitol, and glucose; the flavor is a natural flavor or an artificial flavor.
- 根据权利要求2所述的普瑞巴林组合物,其特征在于,还包括助流剂,所述助流剂为微粉硅胶、滑石粉、硬脂酸镁中的任意一种或几种。The pregabalin composition according to claim 2, is characterized in that, also comprises glidant, and described glidant is any one or more in micropowder silica gel, talcum powder, magnesium stearate.
- 权利要求1-8任一项所述的普瑞巴林组合物在制备普瑞巴林片剂上的应用。Application of the pregabalin composition described in any one of claims 1-8 in the preparation of pregabalin tablets.
- 一种普瑞巴林片剂的制备方法,其特征在于,包括如下步骤:A preparation method of pregabalin tablet, is characterized in that, comprises the steps:(1)将各原料药进行门式整粒机整粒,整粒后使普瑞巴林为具有方形晶习的普瑞巴林,粒径范围为D90:350~600μm;(1) Carrying out the granulation of each bulk drug by a door-type granulator, after granulation, the pregabalin is pregabalin with a square crystal habit, and the particle size range is D90: 350-600 μm;(2)将各原辅料除润滑剂外进行混合,过筛,再加入润滑剂混合,得混合颗粒;(2) mixing each raw and auxiliary material except the lubricant, sieving, adding the lubricant and mixing to obtain mixed granules;(3)将混合颗粒经压片机压制,得硬度为4-6kg的素片。 (3) Compress the mixed granules through a tablet machine to obtain plain tablets with a hardness of 4-6kg.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210155830.6 | 2022-02-21 | ||
CN202210155830.6A CN114469880B (en) | 2022-02-21 | 2022-02-21 | Pregabalin composition suitable for powder tabletting and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023155682A1 true WO2023155682A1 (en) | 2023-08-24 |
Family
ID=81483251
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2023/074166 WO2023155682A1 (en) | 2022-02-21 | 2023-02-01 | Pregabalin composition suitable for powder tableting and use thereof |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN114469880B (en) |
WO (1) | WO2023155682A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114469880B (en) * | 2022-02-21 | 2024-02-02 | 广州帝奇医药技术有限公司 | Pregabalin composition suitable for powder tabletting and application thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060270871A1 (en) * | 2005-05-30 | 2006-11-30 | Khanduri Chandra H | Polymorphic form i of pregabalin and processes for its preparation |
CN103271888A (en) * | 2013-06-18 | 2013-09-04 | 上海奥科达生物医药科技有限公司 | Pregabalin orally disintegrating tablet and dispersible tablet and preparation method thereof |
WO2017064192A1 (en) * | 2015-10-14 | 2017-04-20 | Laboratorios Lesvi, S.L. | Pregabalin compositions |
CN112121020A (en) * | 2019-06-24 | 2020-12-25 | 北京万全德众医药生物技术有限公司 | Preparation method of pregabalin orally disintegrating tablet |
CN114469880A (en) * | 2022-02-21 | 2022-05-13 | 广州帝奇医药技术有限公司 | Pregabalin composition suitable for powder tabletting and application thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019238068A1 (en) * | 2018-06-13 | 2019-12-19 | 北京泰德制药股份有限公司 | Sustained-release pregabalin composition and preparation method therefor |
-
2022
- 2022-02-21 CN CN202210155830.6A patent/CN114469880B/en active Active
-
2023
- 2023-02-01 WO PCT/CN2023/074166 patent/WO2023155682A1/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060270871A1 (en) * | 2005-05-30 | 2006-11-30 | Khanduri Chandra H | Polymorphic form i of pregabalin and processes for its preparation |
CN103271888A (en) * | 2013-06-18 | 2013-09-04 | 上海奥科达生物医药科技有限公司 | Pregabalin orally disintegrating tablet and dispersible tablet and preparation method thereof |
WO2017064192A1 (en) * | 2015-10-14 | 2017-04-20 | Laboratorios Lesvi, S.L. | Pregabalin compositions |
CN112121020A (en) * | 2019-06-24 | 2020-12-25 | 北京万全德众医药生物技术有限公司 | Preparation method of pregabalin orally disintegrating tablet |
CN114469880A (en) * | 2022-02-21 | 2022-05-13 | 广州帝奇医药技术有限公司 | Pregabalin composition suitable for powder tabletting and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN114469880A (en) | 2022-05-13 |
CN114469880B (en) | 2024-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2377572T5 (en) | Formulation comprising metformin and vildagliptin | |
US11666567B2 (en) | Bromocriptine formulations | |
JP5461179B2 (en) | Cellulosic micronucleus particles and method for producing the same | |
JP2002003492A (en) | Ziprasidone composition | |
WO2023155682A1 (en) | Pregabalin composition suitable for powder tableting and use thereof | |
WO2011010324A1 (en) | Oral pharmaceutical composition of rasagiline and process for preparing thereof | |
JP2023513444A (en) | Solid amorphous dispersion of dasatinib and uses thereof | |
US20120214820A1 (en) | Orally disintegrating pharmaceutical dosage form containing aripiprazole | |
EP2408424A2 (en) | Dry processing of retigabine | |
WO2010117035A1 (en) | Complex and process for production thereof, and granules and tablets | |
CA3157788A1 (en) | Oral pharmaceutical composition comprising carbamate compound and preparation method therefor | |
TW201315462A (en) | Ibuprofen chewable tablet | |
CN106880611A (en) | A kind of tolvaptan preparation of tolvaptan and water soluble adjuvant containing micronizing | |
EP4268821A1 (en) | Pharmaceutical composition containing pyrroloquinoline quinone trilithium salt nonahydrate compound, capsule, and preparation method therefor | |
AU2012238330B1 (en) | Fast Dissolving Solid Dosage Form | |
CN106890146A (en) | A kind of Oseltamivir phosphate dispersible tablet and preparation method thereof | |
CN110292569B (en) | Acetylcysteine capsule and preparation method thereof | |
CN114028348B (en) | Sildenafil citrate orally disintegrating tablet and preparation method thereof | |
KR102359632B1 (en) | Fast-swellable granules comprising alginic acid or its pharmaceutically acceptable salts, and capsule contaning the same | |
JP7109255B2 (en) | Method for producing pulverized material and method for producing tablet | |
EP3377044A1 (en) | Ibuprofen compositions for direct oral administration | |
JP2022151857A (en) | Orally-disintegrating edoxaban tablet | |
CN115707471A (en) | Clonazepam orally disintegrating tablet and preparation method thereof | |
CN116549407A (en) | Eszopiclone pharmaceutical composition and preparation method thereof | |
CN115212173A (en) | Ambroxol hydrochloride spherical sustained-release particles, preparation method and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23755686 Country of ref document: EP Kind code of ref document: A1 |